A study of the relationship between feline infectious peritonitis and retroviruses in cats

02.2019, Translation 7.5.2021
Aydin Hakan, Yildirim Serkan
Original complete article: Investigation of the relationship between feline infectious peritonitis and retroviruses in cats

Abstract

Feline infectious peritonitis (FIP) infection is a highly pathogenic and fatal systemic inflammatory disease of cats. Although FIP infection is associated with the immune system, there are several predisposing factors for the disease. FIP has a high degree of interaction with other infectious agents. Feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) infections play a predisposing role by reducing immunity to FIP. This study was performed with Turkish Van cats, a cat breed specific to the Turkish Lake Van region, between 2014 and 2015. Ascites and signs of organ damage in 15 Van cats were identified by pathological analysis at Van Yüzüncü Yıl University. Polymerase chain reaction (PCR) was used to examine the presence of FIV and FeLV in the homogenate of brain, lung, liver, kidney, spleen and intestinal samples with lesions. FIV was identified in 1 (6.7%) of 15 cats and all cat samples were positive for FeLV (100%). Phylogenetic analysis of the positive samples revealed that it was endogenous FeLV. In the FIV phylogenetic analysis, our study strain was found to belong to the FIV subgroup B. The fact that FIP-positive cats were also positive for FeLV has drawn attention to the pathogenesis of endogenous-FeLV in malignancies, which has not yet been understood. In particular, it was concluded that the prevalence of FIP infection can be reduced by paying attention to the vaccination of young cats with FIV and FeLV in environments with a high cat population.

Introduction

Feline infectious peritonitis (FIP) is a fatal disease caused by the feline infectious peritonitis virus (FIPV), which is the result of a coronavirus mutation (FCoV). While FCoV has an enteric form, FIPV is a pathogenic type with a systemic infection. The dramatic increase in the cat population after World War II and the subsequent placement of cats in shelters paved the way for the most important scenario of the FIP. FCoV is thought to spread in the cat population due to their mass concentration, leading to mutant FIPV [1, 2]. Although the disease is not common in older cats, FIP infection is one of the leading causes of death in young cats aged 3 to 24 months. There are two types of FIP: effusive (wet) and granulomatous (dry). While the wet form is the most common and takes the form of inflammatory exudate in body cavities, the granulomatous form attacks the organs [1, 3]. The hypothesis of FIP is based on the fact that viral replication in cats with FCoV occurs in enterocytes. However, another variant of FIPV that can replicate in macrophages due to a mutation in the FCoV genome has also been published. [4]. FIP is a slow, progressive disease and can last for weeks or months. However, retroviral opportunistic infections such as feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV), which cause immunosuppression, lead to the inevitable death by reduced immunity to FIP and accelerated disease. Although cats overcome FIP infection, secondary FeLV and FIV infection reactivates FIPV and dies in a short time. [4-6].

The Retroviridae family, which includes immune-suppressing viruses such as FIV and FeLV, has a linear, single-stranded, non-segmented, genome with a positive RNA polarity of 8-13 kb. Retroviruses that are morphologically enveloped and have icosahedral symmetry contain gag, pol and envelope gene regions [7, 8].

The immune system plays an important role in the clinical manifestations of FIP (wet / granulomatous). In granulomatous cases (dry FIP), T-cell mediated cellular immunity and humoral immunity are key. In FeLV infections in particular, FeLV infection affects the clinic of FIP infection due to disruption of this immune system mechanism. [9]. In addition, cats with FIP infection in the form of a latent or limited infection may experience re-infection due to FeLV. This will again result in death due to the FIP [5]. FIV infection is one of the most important co-infection factors in FIP outbreaks in cats with FCoV. It is reported that FCoV can achieve a very high rate of replication in immunosuppressed cats due to FIV infection, and that this may be a predisposing factor for FCoV to FIPV mutation. In cats infected with FIV and FCoV, FIV causes a high degree of FCoV replication and may lead to an outbreak of FIP in a short time. [1]. These retroviruses, which disrupt the immune system, are the most important clinical indicators of FCoV mutation. [1]. In the case of FIP-induced immune suppression, the transmission of opportunistic pathogens such as FIV / FeLV may occur. [10, 11]. Although there are currently commercial vaccines against FIV and FeLV, there is no protective vaccination or effective treatment against FIP in Turkey. [12].

This study was conducted to determine the interactions between FIPV infection and retrovirus co-infection (FIV / FeLV) in Van cats, a cat breed originating in Turkey.

Materials and methods

The population for the study consisted of a total of 15 cats with suspected FIP, which were transported to Van Yüzüncü Yıl University between 2014 and 2015 for pathological analysis of the death of the Turkish Van cat breed. Refrigerated tissue samples from the brain, lungs, liver, kidneys, spleen and intestines were sent refrigerated to a virology laboratory. For histopathological examinations, tissue samples from all tissues were taken into 10% formalin solution. After 48 hours of fixation in formalin solution, the samples were washed with running tap water for 10 hours. After passing through alcohol (70 °, 80 °, 90 °, 96 ° and 100 °) and xylene, they were immersed in paraffin blocks. Four thick sections were taken from each block to prepare slides on a slide. For histopathological examination, they were stained with hematoxylin-eosin (HE) and examined by light microscopy.

Immunohistochemical examination

All sections taken into adhesion (poly-L-lysine) immunoperoxidase slides were passed through xylene and alcohol series for deparaffinization and dehydration. They were then washed for 5 minutes in distilled water, 5 minutes with phosphate buffer (PBS, pH 7.2) and the endogenous peroxidase was inactivated by standing in 3% H202 for 3 minutes. After washing for 5-10 minutes in PBS, they were incubated for 5 minutes with Protein Block, which is compatible with all primary and secondary antibodies, to prevent non-specific staining of the substrate. At the end of the incubation, the excess blocking solution remaining on the tissue sections was removed and drops of primary antibodies (VGEF, caspase 3, caspase 8, caspase 9, PCNA, neuronectin, TRPM 1, TRPM 2, α synuclein, apelin) and PBS in the control group were used without washing. In accordance with the primary antibody, they were left to stand overnight at +4°C. After washing twice for 5 min. with PBS, they were incubated for 10-30 min. at room temperature with biotinylated secondary antibody. Sections washed again with PBS were left to stand in streptavidin-peroxidase for 10-30 minutes, then washed in the same manner with PBS. After washing, 3-3 'diaminobenzidine (DAB) chromogen was added to the sections and the mixture was left to stand for 5-10 minutes. according to the uptake of the chromogen. After immersion in Mayer's hematoxylin for 1-2 minutes for staining, they were rinsed with running water. They were then passed through an alcohol and xylene series, covered with coverslips and examined with a light microscope (Leica DM 1000). The sections were scored as negative (-), mild (+), moderate (++) and severe (+++) positive according to their immunopositivity.

Investigation of retroviral infections in FIP positive cats

For FIV and FeLV DNA testing of FIP-positive cats, liver, spleen, kidney and brain tissue samples with lesions were taken according to pathological analysis. These tissue samples were combined to prepare a homogenate. Nucleic acid isolation was performed using a supernatant from this tissue homogenate using a commercial kit (GF-1 Nucleic Acid Extraction Kits, Vivantis, Malaysia). The resulting nucleic acid suspension was used as a template for PCR for FIV and FeLV analysis. For FIV DNA screening, nested-PCR was performed using primer pairs specific for the V3-V6 region of the env gene (Table 1). [13]. For FeLV detection, PCR was performed using primer pairs specific for the FeLV env gene region [14]. The primer sequences and product sizes are listed in Table 1.

Example5′-3 ′ sequencePolaritySpecificitySize (bp)
Env FwTAY TGG GCC TGT AAC ACY G+FeLV508
Env RvCGC TGT TTT AGT CTT TCT CTT A–FeLV
VE1SGAG TAG ATA CWT GGT TRC AAG+FIV1211
VE1RCAT CCT AAT TCT TGC ATA GC–FIV
nVE2SCAA AAT GTG GAT GGT GGA AY+FIV859
nVE2RACC ATT CCW ATA GCA GTR GC–FIV
Table 1: Details of oligonucleotides used in the study

Sequential and phylogenetic analysis

After gel electrophoresis, FIV / FeLV positive PCR products were subjected to sequence analysis. The raw data obtained after sequencing were confirmed by GenBank (NCBI National Center for Biotechnology Information / BLAST). Sequences of reference strains and studied samples were arranged by BioEdit program (version 7.0.5) [15]. Phylogenetic analysis was performed using the MEGA program (version 6.0) by the neighborhood method [16].

The results

Pathological findings

At necropsy, gray-white granulomatous lesions in the spleen, liver, kidneys, intestines, lungs and cerebral organs and serous atrophy were observed macroscopically in adipose tissue (Figure 1). In the effusion form, the mucous membranes were found to be strongly icteric and there was a discharge of 1-1.5 l in the abdominal cavity (Figure 2).

Figure 1: Non-fusion form, pyogranulomas clearly visible in seroses of liver, spleen and intestine
Figure 2: Efusion form, approximately 1.5 l of effusion fluid in the abdominal cavity

Microscopic examination revealed, especially in the non-fusible form, pyogranulomatous lesions, necrotic in the middle, spleen, liver, kidneys, intestines, lungs and brain tissues, surrounded by neutrophils, macrophages, lymphocytes and plasma cells (Figure 3). Vasculitis was found in the vessels in these organs (Figure 4). While these granules were generally observed near the serosa, some of them progressed to parenchymal tissue, especially in the kidneys.

Figure 3: Liver, pyogranuloma and mononuclear cell infiltrations consisting of neurophilic leukocytes and mostly with necrotic mass in the middle; H&E, Molding: 50 µm
Figure 4: Renal tissue, FIP positive in tubular epithelium and interstitial intermittent macrophages, IHC-P, Rail: 100 µm

Virological findings

FIV / FeLV DNA was examined by molecular methods in 15 Van cats with FIP diagnosed by pathological analysis. As a result of PCR analysis, FeLV DNA was detected in all 15 cats (100%). In the phylogenetic analysis of FeLV strains in our study and GenBank reference strains, FeLV strains formed two phylogenetic groups: exogenous and endogenous. Sheep and horse retroviruses have been used as a non-member group. In phylogeny, it was observed that all our study strains coalesced together with endogenous FeLV (enFeLV) (Figure 5).

Figure 5: Phylogenetic tree based on the 508 bp nucleotide sequence of 15 FeLV strains generated by Neighbor-Joining using MEGA 6.0 software. Equine and ovine retroviruses were used as a non-member group. Round symbols (•) indicate Turkish tribes

PCR analysis identified FIV in 1 (6.7%) from 15 samples. Subsequently, a sequential reaction and phylogenetic analysis of the FIV strain was performed. Phylogenetic analysis of the FIV strain obtained from our study and reference strains from GenBank showed that the FIV strains were divided into 6 different subtypes from A to F. Our FIV strain was classified as FIV subtype B along with Turkish and Japanese strains (Figure 6).

Figure 6: Phylogenetic tree based on the 859 bp nucleotide sequence of FIV strains generated by Neighbor-Joining using MEGA 6.0 software. The square symbol indicates a Turkish tribe

Discussion

FIP is a systemic infection associated with the immune system caused by coronaviruses. This insidious and deadly infection significantly threatens domestic and street cats that share the same environment with humans, and even breeds of protected cats such as Van cats. Eliminating predisposing factors is the first combat strategy against FIP infection, for which there is not yet an effective method of prevention and treatment in Turkey. Of these factors, cleaning, hygiene and negative interaction in ordinary living spaces are important. Immunosuppressive diseases, such as FIV and FeLV, are the most important predisposing factors for the development of FIPV, a mutant form of coronavirus.

In our study, pathological analysis revealed FIP infection in cats of Van, a breed native to Turkey. Subsequently, the presence of FIV and FeLV was examined in tissue samples obtained from these cats.

FeLV and FIV are pathogenic infectious agents that cause immunosuppression mortality in domestic cats. While FIV is similar to human HIV infection, FeLV causes immunosuppressive, neoplastic, and hematopoietic disorders. [17]. Retroviral infections of cats are the most important trigger for FIP infection in cat homes and shelters. Successful results against retroviral infections have been achieved thanks to the aggressive policies of many Western countries, such as the eradication of infections through testing and vaccination. [18]. Although vaccines against FIV / FeLV infections exist in Turkey, an adequate and controlled vaccination program has not yet been established.

In our study, FeLV was detected in all cats with FIP. FeLV is divided into 6 groups: A, B, C, D, E and T. These types, called exogenous FeLV, are responsible for leukemia and tumor formation in cats. Endogenous FeLV (enFeLV) are FeLV sequences transfected into the genome of domestic cats. enFeLV proviruses are found in various organs and tissues and perform translation and transcription. However, due to the lack of essential parts of the viral genome, it cannot become an infectious viral particle. However, infection of a cat with exogenous FeLV (field strain) leads to recombination between the two (endogenous / exogenous) and transforms enFeLV into an infectious virus particle. However, it is still unclear whether enFeLV may be responsible for malignant formations in cats with lymphoma where exogenous strains are not detected. [19].

In our study, FeLV was detected in all tissue suspensions with pathological lesions collected from Van cats. Phylogenetic analysis showed that they were all enFeLV. Although this suggests that enFeLV may mutate and cause malignant formations, there is no information in the literature to support this hypothesis. There are several studies on coronavirus infection of cats in Turkey. In a study by Pratelli et al., FCoV seropositivity was determined in 62% cats living in environments such as shelters. [20]. In a study by Sahna et al. by molecular methods, the rate was identified by FCoV 54% [21]. A study in Turkey identified a rare ocular form of FIP infection in cats [22]. In a retrospective study of FCoV, FIV and FeLV in 169 sick cats in Turkey, seroprevalence ratios were determined to be 37%, 11% and 1% [23]. Similarly, in a study investigating FCoV, FIV and FeLV in chronic gastrointestinal, urinary, symptomatic and healthy cats in Turkey, viral substances were detected in 45.5%, 9.5% and 20.5%, respectively [24]. In our study, one cat was found to be co-infected with FIV and FeLV. In the phylogenetic analysis of the FIV strain identified in our study, it was found to be a subtype group B. In a previous study performed in cats in Turkey, subtype B was identified in parallel with our results. [25]. In a study of FIV and FeLV infections in cats, the incidence rates of FIV and FeLV were found to be 22.3% and 5.8%, respectively. [26]. Because our study was limited to a specific group, a relatively low FIV / FELV rate was achieved.

Conclusions

Eliminating predisposing factors is the first combat strategy against FIP infection, for which a method of prevention and treatment is not yet effective in Turkey. Although there are vaccines against FIV / FeLV infections that are predisposing factors for FIP, an adequate and controlled vaccination program has not yet been established. Due to the increased incidence of FCoV and predisposing factors, vaccination and awareness of cat owners is important in this regard in order to minimize the spread of FIPV. There is a need to establish a national eradication and control policy for agents such as FIPV and FeLV, which prepare the ground for FIPV infection in shelter cats and even in protected cat breeds.

Compliance with ethical standards

Acknowledgement

SY: For a time he worked at Van Yüzüncü Yıl University. At that time, cat samples were obtained. SY: provided cat samples and performed pathological analyzes, HA: performed virological analysis. SY and HA read the whole article and agreed.

Disclosure of conflicts of interest

The authors declare that they are not aware of the conflict of interest.

Declaration of ethical approval

This study was approved by the Ethics Committee of the Veterinary Faculty Unit of Van Yüzüncü Yıl University (Protocol No. 2015/03).

References

  1. Pedersen NC. (2009). A review of feline infectious peritonitis virus infection: 1963-2008. Journal of Feline Medicine and Surgery, 11 (4), 225-258.
  2. Felten S, Weider K, Doenges S, Gruendl S, Matiasek K, Hermanns W, Mueller E, Matiasek L, Fischer A, Weber K, Hirschberger J, Wess G and Hartmann K. (2017). Detection of feline coronavirus spike gene mutations as a tool to diagnose feline infectious peritonitis. Journal of Feline Medicine and Surgery, 19 (4), 321-335.
  3. Riemer F, Kuehner KA, Ritz S, Sauter-Louis C and Hartmann K. (2016). Clinical and laboratory features of cats with feline infectious peritonitis – a retrospective study of 231 confirmed cases (2000-2010). Journal of Feline Medicine and Surgery, 18 (4), 348-356.
  4. Hartmann K. (2017). Feline infectious peritonitis – new developments in pathogenesis, diagnosis, and management. The Thai Journal of Veterinary Medicine, 47, 97-100.
  5. Pedersen NC. (1987). Virologic and immunologic aspects of feline infectious peritonitis virus infection. Advances in Experimental Medicine and Biology, 218, 529-550.
  6. Pedersen N, Evermann J, McKeirnan A and Ott R. (1984). Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683. American journal of veterinary research, 45 (12), 2580-2855.
  7. Liu D. (2016). Feline Leukemia Virus. Molecular Detection of Animal Viral Pathogens, First edition. GRC Press. chapter22, 197.
  8. Burmeister T. (2001). Oncogenic retroviruses in animals and humans. Reviews in Medical Virology, 11 (6), 369-380. [9] Hardy WD. (1982). Immunopathology induced by the feline leukemia virus. Springer Seminars in Immunopathology, 5 (1), 75-106.
  9. Pedersen N. (1976). Feline infectious peritonitis: something old, something new. Feline practice, 6 (3), 42-51.
  10. Cotter SM, Gilmore CE and Rollins C. (1973). Multiple cases of feline leukemia and feline infectious peritonitis in a household. Journal of the American Veterinary Medical Association, 162 (12), 1054-1058.
  11. Lewis CS, Porter E, Matthews D, Kipar A, Tasker S, Helps CR and Siddell SG. (2015). Genotyping coronaviruses associated with feline infectious peritonitis. Journal of General Virology, 96 (6), 1358-1368.
  12. Nishimura Y, Nakamura S, Goto N, Hasegawa T, Pang H, Goto Y, Kato H, Youn HY, Endo Y, Mizuno T, Momoi Y, Ohno K, Watari T, Tsujimoto H and Hasegawa A. (1996). Molecular characterization of feline immunodeficiency virus genome obtained directly from organs of a naturally infected cat with marked neurological symptoms and encephalitis. Archives of virology, 141 (10): 1933-1948.
  13. Ramirez H, Autran M, Garcia MM, Carmona MA, Rodriguez C and Martinez HA. (2016). Genotyping of feline leukemia virus in Mexican housecats. Archives Virology, 161 (4), 1039-1045. Aydin and Yildirim / GSC Biological and Pharmaceutical Sciences 2019, 06 (02), 071–078 78
  14. Hall TA. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98 / NT. Nucleic acids symposium series: [London]: Information Retrieval Ltd., c1979-c2000.
  15. Tamura K, Stecher G, Peterson D, Filipski A and Kumar S. (2013). MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Molecular Biology and Evolution, 30 (12), 2725-2729.
  16. Miyazawa T, Ikeda Y, Maeda K, Horimoto T, Tohya Y, Mochizuki M, Vu D, Vu GD, Cu DX, Ono K, Takahashi E and Mikami T. (1998). Seroepidemiological survey of feline retrovirus infections in domestic and leopard cats in northern Vietnam in 1997. Journal of veterinary medical science, 60 (11), 1273-1275.
  17. Weijer K, Uijtde Haag F and Osterhaus A. (1986). Control of feline leukemia virus infection by a removal program. Veterinary Record, 119 (22), 555-556.
  18. Krunic M, Ertl R, Hagen B, Sedlazeck FJ, Hofmann-Lehmann R, von Haeseler A and Klein D. (2015). Decreased expression of endogenous feline leukemia virus in cat lymphomas: a case control study. BMC Veterinary Research, 11, 90.
  19. Pratelli A, Yesilbag K, Siniscalchi M, Yalcm E and Yilmaz Z. (2009). Prevalence of feline coronavirus antibodies in cats in Bursa province, Turkey, by an enzyme-linked immunosorbent assay. Journal of Feline Medicine and Surgery, 11 (10), 881-884.
  20. Can-Sahna K, Soydal Ataseven V, Pinar D and Oguzoglu TC. (2007). The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. Journal of Feline Medicine and Surgery, 9 (5), 369-372.
  21. Baydar E, Eroksuz Y, Timurkan MO and Eroksuz H. (2014). Feline infectious peritonitis with distinct ocular involvement in a cat in Turkey. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, 20 (6), 961-965.
  22. Tekelioglu BK, Berriatua E, Turan N, Helps CR, Kocak M and Yilmaz H. (2015). A retrospective clinical and epidemiological study on feline coronavirus (FCoV) in cats in Istanbul, Turkey. Preventive Veterinary Medicine, 119 (1-2), 41-47.
  23. Oğuzoğlu T, Muz D, Timurkan M, Maral N and Gurcan I. (2013). Prevalences of feline coronavirus (FCoV), feline leukemia virus (FeLV), feline immunodeficiency virus (FIV) and feline parvovirus (FPV) among domestic cats in Ankara, Turkey. Veterinary Medical Review, 164 (11), 511-516.
  24. Oguzoglu TC, Timurkan MO, Muz D, Kudu A, Numanbayraktaroglu B, Sadak S and Burgu I. (2010). First molecular characterization of feline immunodeficiency virus in Turkey. Archives of Virology, 155 (11), 1877-1881.
  25. Yilmaz H, Ilgaz A and Harbor DA. (2000). Prevalence of FIV and FeLV infections in cats in Istanbul. Journal of Feline Medicine and Surgery, 2 (1), 69-70.

Coronaviruses as a cause of vascular disease: a comparative medicine approach

29.1.2021, Translation 2.5.2021
Alison E. Stout DVM, Nicole André LVT, Joshua Zimmerberg MD PhD, Susan C. Baker PhD and Gary R. Whittaker PhD
Original article: Coronaviruses as a cause of vascular disease: a comparative medicine approach

Contact the author: e-mail: grw7@cornell.edu. 618 Tower Rd., Ithaca NY 14853 USA.

Abstract

COVID-19 caused by SARS-CoV-2 often manifests as a respiratory disease including cough, dyspnoea, fever and olfactory loss. However, other manifestations of the disease occur in many organ systems, at least in part due to vasculitis and endothelitis. COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) has recently been identified as part of SARS-CoV-2 infection. In feline medicine, feline coronavirus is a common pathogen that can lead to a deadly disease called feline peritonitis (FIP). Like human COVID-19, the clinical manifestations of FIP are due in part to coronavirus-induced vasculitis, which can also lead to fatal multisystemic inflammatory syndrome in cats. Studies investigating how feline coronavirus infection can cause disseminated vasculitis in FIP cats will provide new information that may help people understand COVID-19. We strive for a comparative medicine approach to tackling coronavirus diseases.

The COVID-19 pandemic in 2019-2020 is caused by the recently discovered zoonotic beta-coronavirus classified as SARS-CoV-2. COVID-19 often manifests as a respiratory disease manifested by fever, cough, dyspnoea, olfactory loss, headache, and malaise. More severe disease may include acute respiratory distress syndrome (ARDS); however, the disease also appears to affect other organ systems, including the gastrointestinal, central nervous system (CNS), cardiovascular, renal, hepatic, endocrine, dermatological, hematological, and ophthalmic systems.17 These systemic symptoms are thought to be due to viral endothelial cell infection and endothelitis49 leading to vasculitis.5 COVID-19 can be considered both a respiratory disease and a vascular disease, with widespread viral tropism and high transmissibility contributing to the current public health crisis and the differentiation of SARS-CoV-2 from SARS-CoV, despite the receptor (ACE2) common to both viruses.

After studying the history and pathogenesis of feline coronavirus, we see parallels between COVID-19 and feline infectious peritonitis (FIP) with a wide variety across human and feline coronavirus infections, as originally found in SARS.41 Feline coronavirus (FCoV) in cats is generally considered to be an initial gastrointestinal or rarely respiratory infection that results in FIP, a systemic vascular disease with high morbidity and mortality in some animals.46 This feline disease, originally called chronic fibrinous peritonitis, was first described in 1963. 22; shortly afterwards, the etiological agent (causative agent) was recognized as a coronavirus. This disease, now called feline infectious peritonitis (FIP), occurs worldwide, is almost always fatal, and mainly affects young cats (under 2 years of age).28,38 The etiological agent responsible for most cases of FIP is feline coronavirus (FCoV), alpha coronavirus.25 While FCoV transmission and infection are widespread in domestic cats, systemic disease develops in only a small subset of animals (Figure 1). Common to these various forms of the disease is the identification of virus-induced vasculitis.27 This review highlights the similarities between COVID-19 and FIP and opens up opportunities for cooperation between the medical and veterinary communities in the fight against these devastating diseases.

Figure 1: FIP develops only in a subset of infected cats, despite the widespread spread of FCoV. Similarly, according to current knowledge, many cases of SARS-CoV-2 infection are characterized by a mild or asymptomatic course.

Clinical and pathological profile of feline coronavirus infection: parallels with COVID-19

Like COVID-19 in humans, FIP is involved in many manifestations of the disease in cats (Figure 2), which are described as "variably manifested by multiple organ failure, seizures, generalized effusion, or shock."14 The disease is commonly classified in one of two clinical forms, effusive or "wet" (characterized by accumulation of protein effusion mainly in the peritoneal or pleural cavities) and non-fusive or "dry" (characterized by granulomatous lesions in many organs, including the brain).19 A “mixed form” is also considered, in the clinical spectrum of which granulomatous and pyogranulomatous lesions occurring in the serous part of the liver, kidneys and intestines are common. The spectrum of pathologies observed in FIP includes serositis, hepatitis, nephritis, uveitis and chorioretinitis.38,55 Neuropathological manifestations of FIPV in cats include meningitis, meningoencephalitis, ependymitis, and choroidal plexitis with inflammation ranging from lymphoplasma to pyogranulomatous, and often including vasculitis and perivasculitis. Ophthalmic manifestations, including uveitis and chorioretinitis, are also common. Case reports point to associated heart lesions, including myocarditis and fibrinous epicarditis.12,34 Dermatological lesions that are less commonly observed in FIP include erythema, nodules, and papules.4,8,10 In some cases, early respiratory symptoms have been reported8,54 and in some cats, immunostaining identified the virus in the lung parenchyma.27 Our latest laboratory has confirmed the presence of the virus in the upper respiratory tract by immunostaining.1

Figure 2: Vasculitis caused by FCoV infection can affect many body systems. Since the first descriptions in the 1960s, numerous studies have revealed various forms of the disease.

A similar feature in FIP outbreaks and patients with COVID-19 is extensive vascular involvement.3,5,20 In one of the first reports recognizing vascular involvement in FIP cases, four types of lesions were described: “perivascular edema,” “vascular wall degeneration,” “endothelial proliferation,” and “adventitial and/or perivascular infiltration.”20 In 1989, Boudreaux and colleagues described FIP lesions in several cats as "obliterating" vascular walls. Similarly, August concluded in 1984 that "FIP could be more accurately termed feline coronavirus vasculitis."3 As a naturally occurring disease in cats, FIP and FCoV infection provide an opportunity to understand the pathogenesis of SARS-CoV-2, especially with regard to the co-development of vascular manifestations.

Although observations of myocarditis, rhinitis or skin lesions in FIP are rare, they allow comparison with COVID-191,8,12,42. Frostbite-like lesions, a condition colloquially called "COVID-fingers", have been reported in several patients with COVID-19, although the direct association of these manifestations with COVID-19 remains open.30,33 In cats, a similar condition is known as plasma cell subdermatitis and may also be associated with FCoV. Plasma cell pododermatitis manifests as paw inflammation along with the potential for color changes, ulcerations, and cracks.40 In the case of feline subdermatitis, an association with an infectious disease has been suspected.11 In addition to observing similar paw lesions in FCoV-secreting cats, our laboratory has previously identified subdermatitis in cats due to FIP. Although "COVID fingers" and subdermatitis in cats are rare consequences of infection, they further highlight the spectrum of similarities between COVID-19 and FIP.

One of the characteristic symptoms of COVID-19 is anosmia (loss of smell). Also, in most cases of FIP, the onset of anorexia is common.38,53 Although a non-specific clinical symptom that can be attributed to many different causes, anorexia can be attributed to loss of odor perception - an extremely important sensation that drives appetite in cats. While anosmia is difficult to measure in cats, the relationship between olfactory bulb infection and possible spread to the brain by human and feline coronaviruses deserves further evaluation, especially with regard to the neurological manifestations of both diseases.14,29

Immune component of FIP disease

Based on previous observations of complement and immunoglobulin circulation, including immune complexes, FIP is classically characterized as immune-mediated.24,39 In particular, type III hypersensitivity and Arthus-like reactions lead to the development of immune complexes that can build up in the walls of blood vessels, leading to vasculitis. Despite attempts to classify FIP as a type III hypersensitivity reaction, further work by Kipar and colleagues has shown numerous differences.26,27 Type III hypersensitivity has also been studied in patients with COVID-19.43 The importance of FIP as a type IV hypersensitivity reaction with apparent perivascular lesions consisting of T-lymphocytes, granulocytes and a characteristic feature of FIP, macrophage infiltrates, was also evaluated.36 Delayed-type hypersensitivity is observed in cats inoculated intradermally with FCoV, leading to perivascular cellular infiltrates of macrophages, neutrophils and lymphocytes in the absence of immune complexes.52 However, cellular extravasation associated with FIP lesions contributes to endothelial disruption and the inflammatory response that underlies FIP.27 Specifically, antigen (LFA) -1 associated with β2 integrin adhesion molecules and lymphocytes, β1 integrin very late antigen (VLA) -4 and β2 macrophage antigen (Mac-1) have been demonstrated to be increased in peripheral blood leukocytes isolated from cats with FIP.35 Integrins (LFA) -1 and (VLA) -4 play an important role in neutrophil and monocyte migration across the endothelium and are involved in the development of vasculitis in other disease processes,9,47 while (Mac-1) may play an additional role in the development of thrombosis.51 The hypothetical role of endothelitis, which underlies COVID-1949, parallels previous findings on FIP and the resulting acute vasculitis.

The interaction between vascular pathogenesis and hemodynamics has long been known in FIP.53 In addition to peripheral pyogranulomatous lesions, phlebitis, endothelial edema with inflammatory infiltrates of tunica media, thrombophlebitis and thrombosis were observed in cats experimentally infected with FCoV, classical FIP.53 Additionally, thrombocytopenia, anemia, jaundice, decreased clotting factors VII-XII, increased antithrombin III, and prolonged activated partial thromboplastin time, prothrombin time, and thrombin time are observed after experimental infection.7,53 Thus, the end result for some cats with FIP is the development of disseminated intravascular coagulation.7,53 This is in contrast to the course in human patients with JIS, who are often anticoagulated at some point in their hospital stay, and the rare development of DIC in humans is associated with a worse course in COVID-19.48 The fibrin product D-dimer, a DIC marker, has been studied rarely in cats with FIP, but has been increased in two cases - as expected, observations in patients with COVID-19 have shown this.

The development of FIP in a subset of cats, although most FCoV-infected cats undergo only a subclinical phase, is thought to be the result of an initial immune response.37 Strong cell-mediated immunity (CMI) together with humoral immunity is thought to lead to a subclinical course of the disease, while a lack of CMI leads to an effusive form of the disease and partial CMI leads to a dry form of the disease.37 Similarly, with respect to the immune response, multisystem inflammatory syndrome in children (MIS-C), which may be a manifestation of SARS-CoV-2, has recently been described.16which may develop due to a delayed response to interferon or due to an aberrant IgG response promoting disease progression.44 In addition to MIS-C, multisystem inflammatory syndrome in adults (MIS-A) has been described as a result of SARS-CoV-2 exposure.32

Antibody-dependent exacerbation of infection

In the case of SARS-CoV-2, there were concerns about antibody-dependent enhancement (ADE) infection,13 largely based on experience with other human viruses, such as respiratory syncytial virus, influenza and dengue; despite the need for caution, formal evidence linking ADE to COVID-19 clinical outcomes remains insufficient.2 In cats, it is noteworthy that the involvement of ADE in FCoV infection and the development of FIP with antibodies that would provide means for FCoV to gain macrophage entry has long been considered.21 So far, despite several trials, a viable FCoV / FIP vaccine is still not available.45,50 In contrast to these FIP vaccine studies, preliminary immunization results for COVID-19, for example with stabilized spike immunogens, documented neutralizing, not potentiating, antibody responses.23

Perspectives

COVID-19 is a complex and challenging disease in humans, and similarly, FIP is a complex disease in cats with many factors contributing to the outcome of the disease. By analogy with the persisting question in metastatic tumor research, "seed and soil", the availability of immunological, pathological and physiological samples and data on these similarly fatal inflammatory syndromes from two different coronaviruses in their own host species allow testing of structure / function hypotheses in venous vasculitis . In addition, due to the lack of enthusiasm for clinical biopsy of human patients with fulminant COVID-19 and the great difficulty in achieving good preservation of pathological specimens, it will take a very long time to learn more about the presence or absence of coronavirus in human patients at baseline and during their progression. inflammatory phase of COVID-19.

As a naturally occurring disease with many parallels with COVID-19, we think that FIP may help in future COVID-19 research. Both baseline vasculopathy in both FIP and COVID-19 underline the need to think of these diseases as multisystemic rather than organ-specific diseases. Although often considered a key enteric mode of transmission for FCoV, it is clear that the oropharyngus is a robust portal to host entry. Another factor to consider is that SARS-CoV-2 infects cats.15,18 Although not currently considered a serious disease in cats, it is not a robust animal model for COVID-19, The increased rate of SARS-CoV-2 infection in cats and possible FCoV co-infections raise, in addition to the possibility of viral recombination, concerns about the overlap of pathology and clinical manifestations of human and feline coronaviruses with surprisingly similar vascular disease profiles. However, the fact that SARS-CoV-2 naturally infects cats may offer a model for preclinical evaluation of SARS-CoV-2 vaccines. We believe that further studies are needed to investigate how coronaviruses can cause vascular disease in order to eliminate these devastating diseases, and FIP provides a platform for joint clinical trials bridging feline and human medicine.

Financing

AES is supported by the NIH Comparative Medicine Training Program T32OD011000. GRW is funded by NIH grants R01AI135270 and R21AI135373, SCB is funded by NIH grant R01 AI085089. FIP research in the author's laboratories is funded in part by the Winn Feline Foundation and the Cornell Feline Health Center.

Thanks

We thank Andrew Miller, Robert Goggs, Natalie Zatz and Beth Licitra for critical reading of the manuscript and helpful discussion.

Conflict of interests

The authors are not aware of any conflict of interest.

References

  1. André NM, Miller AD, Whittaker GR. 2020.
    Feline infectious peritonitis virus-associated rhinitis in a cat. Journal of Feline Medicine and Surgery Open Reports 6: 1–6.
  2. Arvin AM, Fink K, Schmid MA, Cathcart A,
    Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW. 2020. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584: 353363.
  3. August JR. 1984. Feline Infectious Peritonitis: An Immune-Mediated Coronaviral Vasculitis. Veterinary Clinics of North America: Small Animal Practice 14: 971–984.
  4. Bauer BS, Kerr ME, Sandmeyer LS, Grahn BH. 2013. Positive immunostaining for feline infectious peritonitis (FIP) in a Sphinx cat with cutaneous lesions and bilateral panuveitis. Veterinary Ophthalmology 16: 160–163.
  5. Becker RC. 2020. COVID-19-associated vasculitis and vasculopathy. Journal of Thrombosis and Thrombolysis 50: 499-511.
  6. Biezus G, Cristo TG de, Schade MF da S,
    Ferian PE, Carniel F, Miletti LC, Maciel A da R, Casagrande RA. 2020. Plasma cell subdermatitis associated with feline leukemia virus (FeLV) and concomitant feline immunodeficiency virus (FIV) infection in a cat.
    Topics in Companion Animal Medicine 41:
  7. https://doi.org/10.1016/j.tcam.2020.100475.
  8. Boudreaux MK, Weiss RC, Cox N, Spano JS.
  9. Evaluation of antithrombin-III activity as a coindicator of disseminated intravascular coagulation in cats with induced feline infectious peritonitis virus infection. American Journal of Veterinary Research 50: 1910–1913.
  10. Cannon MJ, Silkstone MA, Kipar AM. 2005. Cutaneous lesions associated with coronavirusinduced vasculitis in a cat with feline infectious peritonitis and concurrent feline
    immunodeficiency virus infection. Journal of Feline Medicine and Surgery 7: 233–236.
  11. Coll-Vinent B, Cebrián M, Cid MC, Font C,
    Esparza J, Juan M, Yagüe J, Urbano-Márquez Á, Grau JM. 1998. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis & Rheumatism 41: 435–444.
  12. Declercq J, De Bosschere H, Schwarzkopf I, Declercq L. 2008. Papular cutaneous lesions in a cat associated with feline infectious peritonitis. Veterinary Dermatology 19: 255–258.
  13. Diesel A. Image Gallery: Immune-Mediated Skin Diseases. Clinician's Brief [Internet]. 2020 [cited 2020 September 28]. Available from: http://www.cliniciansbrief.com/article/imagegallery-immune-mediated-skin-diseases
  14. Ernandes MA, Cantoni AM, Armando F,
    Corradi A, Ressel L, Tamborini A. 2019. Feline coronavirus-associated myocarditis in a domestic longhair cat. Journal of Feline Medicine and Surgery Open Reports 5: 1–5.
  15. Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. 2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature Biotechnology 38: 789–791.
  16. Foley JE, Rand C, Leutenegger C. 2003. Inflammation and changes in cytokine levels in neurological feline infectious peritonitis. Journal of Feline Medicine and Surgery 5: 313–322.
  17. Gaudreault NN, Trujillo JD, Carossino M,
    Meekins DA, Morozov I, Madden DW, Indran
    SV, Bold D, Balaraman V, Kwon T, et al. 2020. SARS-CoV-2 infection, disease and transmission in domestic cats. Emerging Microbes and Infections.
    https://doi.org/10.1080/22221751.2020.1833687.
  18. Godfred-Cato S, Bryant B, Leung J, Oster ME,
    Conklin L, Abrams J, Roguski K, Wallace B, Prezzato E, Koumans EH, et al. 2020. COVID-
    19-Associated Multisystem Inflammatory
    Syndrome in Children - United States, March-July 2020. Morbidity and Mortality Weekly Report 69: 1074–1080.
  19. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, et al. 2020.
    Extrapulmonary manifestations of COVID-19. Nature Medicine 26: 1017–1032.
  20. Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, et al. 2020. Transmission of SARS-CoV-2 in Domestic Cats. New England Journal of Medicine 383: 592594.
  21. Hartmann K. 2005. Feline infectious peritonitis. Veterinary Clinics of North America: Small Animal Practice 35: 39–79.
  22. Hayashi T, Goto N, Takahashi R, Fujiwara K. 1977. Systemic vascular lesions in feline infectious peritonitis. The Japanese Journal of Veterinary Science 39: 365–377.
  23. Hohdatsu T, Yamada M, Tominaga R, Makino K, Kida K, Koyama H. 1998. Antibodydependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. The Journal of Veterinary Medical Science 60: 49–55.
  24. Holzworth J. 1963. Some important disorders of cats. The Cornell Veterinarian 53: 157–160.
  25. Jackson LA, Anderson EJ, Rouphael NG,
    Roberts PC, Makhene M, Coler RN,
    McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. 2020. An Vaccine mRNA against SARS-CoV-2 - Preliminary Report. New England Journal of Medicine.
    https://www.nejm.org/doi/full/10.1056/nejmoa2 022483.
  26. Jacobse-Geels HEL, Horzinek MC. 1983. Expression of Feline Infectious Peritonitis coronavirus antigens on the surface of feline macrophage-like cells. J. Gen. Virol 64: 1859–1866.
  27. Jaimes JA, Millet JK, Stout AE, André NM,
    Whittaker GR. 2020. A Tale of Two Viruses: The Distinct Spike Glycoproteins of Feline Coronaviruses. Viruses 12: 83. https://doi.org/10.3390/v12010083.
  28. Kipar A, Bellmann S, Kremendahl J, Köhler K, Reinacher M. 1998. Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis. Veterinary Immunology and Immunopathology 65: 243–257.
  29. Kipar A, May H, Menger S, Weber M, Leukert W, Reinacher M. 2005. Morphologic features and the development of granulomatous vasculitis in feline infectious peritonitis. Vet Pathol 42: 321–330.
  30. Kipar A, Meli ML. 2014. Feline Infectious Peritonitis: Still an Enigma? Veterinary Pathology 51: 505–526.
  31. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al.
    Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020 June 1; 77: 683–690.
  32. Mazzotta F, Troccoli T, Bonifazi E. 2020. A new vasculitis at the time of COVID-19.
    European Journal of Pediatric Dermatology 30: 75–78.
  33. Mesquita LP, Hora AS, Siqueira A de, Salvagni FA, Brandão PE, Maiorka PC. 2016. Glial response in the central nervous system of cats with feline infectious peritonitis. Journal of Feline Medicine and Surgery 18: 1023–1030.
  34. Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, Lee EH, PanethPollak R, Geevarughese A, Lash MK, et al.
  35. Case Series of Multisystem Inflammatory
    Syndrome in Adults Associated with SARS-CoV-2
    Infection - United Kingdom and United States, March – August 2020. Morbidity and Mortality Weekly Report 69: 1450–1456.
  36. Noakes A, Majoe S. 2020. Understanding the role that 'COVID toe' has in recognizing the potential extent of COVID-19 infections: a case study. Pathogens and Global Health 114: 283–284.
  37. Oliveira LB, Susta L, Rech RR, Howerth EW. 2014. Pathology in practice: Effusive FIP with fibrinous epicarditis in a cat 245: 899–901.
  38. Olyslaegers DAJ, Dedeurwaerder A,
    Desmarets LMB, Vermeulen BL, Dewerchin HL, Nauwynck HJ. 2013. Altered expression of adhesion molecules on peripheral blood leukocytes in feline infectious peritonitis. Veterinary Microbiology 166: 438–449.
  39. Paltrinieri S, Parodi MC, Cammarata G, Mambretti M. 1998. Type IV hypersensitivity in the pathogenesis of FIPV-induced lesions. Journal of Veterinary Medicine, Series B 45: 151–159.
  40. Pedersen, N. 1983. Feline infectious peritonitis and feline enteric coronavirus infections. Feline Practice 13: 5–20.
  41. Pedersen NC. 2009. A review of feline infectious peritonitis virus infection: 1963-2008. Journal of Feline Medicine and Surgery 11: 225–258.
  42. Pedersen NC, Boyle JF. 1980. Immunologic phenomena in the effusive form of feline infectious peritonitis. American Journal of Veterinary Research 41: 868–876.
  43. Pereira PD, Faustino AMR. 2003. Feline plasma cell podsermatitis: a study of 8 cases. Veterinary Dermatology 14: 333–337.
  44. Perlman S, Netland J. 2009. Coronaviruses postSARS: update on replication and pathogenesis. Nature Reviews Microbiology 7: 439–450.
  45. Redford T, Al-Dissi AN. 2019. Feline infectious peritonitis in a cat presented because of papular skin lesions. The Canadian Veterinary Journal 60: 183–185.
  46. Roncati L, Ligabue G, Fabbiani L, Malagoli
    C, Gallo G, Lusenti B, Nasillo V, Manenti A,
    Maiorana A. 2020. Type 3 hypersensitivity in COVID-19 vasculitis. Clinical Immunology 217: 108487. https://doi.org/10.1016/j.clim.2020.108487.
  47. Rowley AH. 2020. Understanding SARS-CoV-2related multisystem inflammatory syndrome in children. Nature Reviews Immunology 20: 453–454.
  48. Scott FW, Corapi WV, Olsen CW. 1992. Evaluation of the safety and efficacy of PrimucellFIP vaccine. Feline Health Topics 7: 6–8.
  49. Sykes JE. Feline Coronavirus Infection. In: Canine and Feline Infectious Diseases. Elsevier; 2014. pp. 195–208. Available from:
    https://linkinghub.elsevier.com/retrieve/pii/B978
    143770795300020X
  50. Takeuchi T, Amano K, Sekine H, Koide J, Abe T. 1993. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. The Journal of Clinical Investigation 92: 3008–3016.
  51. Tang N, Li D, Wang X, Sun Z. 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis 18: 844–847.
  52. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR,
    Schuepbach RA, Ruschitzka F, Moch H. 2020.
    Endothelial cell infection and endotheliitis in COVID-19. The Lancet 395: 1417–1418.
  53. Vennema H, Groot RJ de, Harbor DA,
    Dalderup M, Gruffydd-Jones T, Horzinek MC, Spaan WJ. 1990. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. Journal of Virology 64: 1407–1409.
  54. Wang Y, Gao H, Shi C, Erhardt PW,
    Pavlovsky A, A. Soloviev D, Bledzka K, Ustinov V, Zhu L, Qin J, et al. 2017. Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα. Nature Communications 8: 15559. https://doi.org/10.1038/ncomms15559.
  55. Weiss RC, Cox NR. 1989. Evaluation of immunity to feline infectious peritonitis in cats with cutaneous viral-induced delayed hypersensitivity. Veterinary Immunology and Immunopathology 21: 293–309.
  56. Weiss RC, Dodds WJ, Scott FW. 1980. Disseminated intravascular coagulation in experimentally induced feline infectious peritonitis. American Journal of Veterinary Research 41: 663–671.
  57. Wolfe LG, Griesemer RA. 1966. Feline infectious peritonitis. Path Vet 3: 255–270.
  58. Ziółkowska N, Paździor-Czapula K, Lewczuk B, Mikulska-Skupień E, PrzybylskaGornowicz B, Kwiecińska K, Ziółkowski H.
  59. Feline Infectious Peritonitis: Immunohistochemical features of ocular inflammation and the distribution of viral antigens in the structures of the eye. Veterinary Pathology 54: 933–944.

FIP Antivirals

1.12.2020, Translation 1.5.2021
Original Cornell University blog post: FIP Antivirals

Summary

  • For families living with a diagnosis of feline infectious peritonitis (FIP) and the veterinarians involved in their care, we understand that the decision to use black market treatment for an otherwise necessarily fatal disease is the ethical dilemma of choosing the lesser of the two evils.
  • Due to concerns about the safety and efficacy of black market GS-441524 counterfeits, combined with the fact that veterinary supervision of such use is full of legal and ethical dilemmas, we cannot currently recommend the use of such treatment.
  • We strongly warn against the widespread use of antiviral therapy as monotherapy in farms and shelters with endemic feline enteric coronavirus (FECV). Widespread use in these conditions is expected to generate antiviral-resistant FIP strains.

Opinion

We received many questions regarding the use of GS-441524 in the treatment of FIP. Here is a summary of GS-441524 and our position on its current use. Research into the use of this compound was first published by Dr. Niels Pedersen of UC Davis in 2018. Team Dr. Pedersen published a follow-up study documenting the use of GS-441524 in naturally occurring cases of FIP in 2019. The results of both studies were unprecedented with the 100% (10/10) recovery rate reported in experimentally infected cats and the 84% (25/31) recovery rate in naturally infected cats. Owned cured cats reported returning to "near normal" within two weeks of treatment. The fever usually subsided during the first 12-36 hours, accompanied by a return of appetite. The effusions subsided within 10-14 days and the jaundice gradually subsided within 2-4 weeks. The conclusion of the 2019 study proposes an optimized treatment protocol for the use of GS-441624 at a dose of 4.0 mg / kg given as a subcutaneous injection once a day for at least 12 weeks.

Although managing a natural infection has been shown to be more challenging than an experimental infection, most cats in the study have responded to treatment. Dr. Pedersen is a pioneer in the field of FIP research and there is no doubt about the legitimacy of its work. Unfortunately, there are many issues surrounding the current use of GS-441524. Most of these concerns are directly related to the fact that this medicine cannot be legally purchased from a regulated source. In addition to blocking consumers' access to the medicine, it has also blocked research into best practice and marginalized the role of veterinarians in treatment decisions.

GS-441524 is owned by Gilead Sciences, an American biopharmaceutical company focused on the development of antiviral drugs. Gilead provided GS-441624 Dr. Pedersen for use in his 2018 and 2019 studies, but refused to market the drug for use in cats because of his close relationship with another promising antiviral drug, remdesivir. Prior to the SARS-CoV-2 pandemic, remdesivir was tested for the treatment of Ebola. In a story complicated by human drug licensing challenges, Gilead feared that any adverse effects of GS-441524 reported in cats would harm remdesivir in the FDA approval process. The market for veterinary medicines - even as promising as GS-441524 - is negligible compared to a potential human blockbuster. Gilead considered the use of GS-441524 for the treatment of FIP as an unnecessary risk that could harm the chances of remdesivirus success and refused to license it for use in cats.

This created a black market with GS-441524, led by overseas businessmen in an effort to take advantage of the despair caused by the FIP diagnosis. Treatment is expensive, ranging from $ 1,000 to $ 10,000. There is no formal regulation of these suppliers or their products on the black market. Veterinary professionals may be at legal risk if they recommend, dispense or administer these unapproved medicines. This combination of factors can prevent treated cats from receiving optimal care. We understand that FIP is otherwise a deadly disease, so these risks may seem acceptable, but we warn that unregulated use of GS-441524 has the potential to develop antiviral resistance and jeopardize the success of FIP treatment in the future.

GS-441524 is a nucleoside analog. When viral RNA polymerase integrates GS-441524 into the viral genome, the replication mechanism is blocked and transcription is terminated prematurely, making it difficult for the virus to replicate. We know from experience with nucleoside analogues designed to treat HIV that these drugs do not completely suppress viral replication. The use of single-drug therapy leads to the development of resistant strains. Our most successful experience with antiviral therapy includes combination therapies targeting various aspects of viral replication. Such combination therapies lead to excellent viral suppression and reduce the incidence of antiviral resistance.

The oral form of the nucleoside analog GS-441524 is currently marketed as a supplement to support the feline immune response. Preliminary study Dr. Dianne Addie states that this treatment stops the secretion of the original enteric coronavirus, also known as FECV. This work investigates the prophylactic use of a nucleoside analog in a multi-cat environment where cats have a high risk of developing FIP. Although these results appear to be positive at first sight, they are a matter of deep concern due to the development of antiviral resistance. Although there is preventive prophylaxis for people at high risk of contracting HIV, it is important to emphasize that this medicine, known as Truvada, is a combination antiviral treatment. Decades of experience with HIV have shown that monotherapies are much more likely to result in resistant antiviral strains.

Dr. Addie makes a compelling case for involving veterinarians and researchers in the use of new FIP therapies. We would like to add that there is an obligation to discourage any use that would lead to the development of antiviral resistance. According to one-health, both wild and domestic cats appear to be susceptible to SARS-CoV-2. This has implications for both the veterinary and human worlds: coronaviruses are well known for their ability to recombine in susceptible hosts, and there is a possibility that we are entering uncharted territory with the emergence of recombinant viruses generated under selective antiviral pressure.

One of the bright spots in the dark cloud of the SARS-CoV-2 pandemic is that we will probably soon be able to put aside concerns about the use of the GS-441524 from the black market. A close relative, remdesivir, recently obtained FDA approval for use in a pandemic SARS-CoV-2 infection in humans. Now that the main obstacle to licensing has been clarified, we are optimistic that this will pave the way for the legal and scientifically based use of GS-441524 in cats. While initial studies of GS-441524 have proven to be very promising, important research is still needed in the wider field. Initial data on the efficacy of remdesivir for treatment with COVID-19 illustrated better results than those found in the larger study. WHO, where the drug has only a slight effect on the results at best.

With regard to combination therapy, other potential antiviral drugs for FIP are possible, in particular the protease inhibitor GC376 has a completely different mechanism of action and is a promising component of combination therapy. (Although not mentioned here, the GC376 black market is a very similar case to GS-441524.) Research into the treatment of COVID-19 in humans will undoubtedly lead to the development of promising therapies for cats. Dr. Pedersen posted preliminary data about 25 such compounds, some of which have shown potential for combination therapy. While awaiting GS-441524 approval, there will be questions regarding the off-label use of remdesivir in cats. We warn that the effects of drugs on different species can be unpredictable and that laboratory research is needed to determine safety and efficacy parameters.

For families living with a diagnosis of feline infectious peritonitis (FIP) and for the veterinarians involved in their care, we understand that the decision to use black market treatment for an otherwise necessarily fatal disease is the ethical dilemma of choosing the lesser of the two evils. We hope that this statement provides a useful reference framework for the history of GS-441524, while emphasizing the potential of antiviral resistance in its unregulated use. Pedersen posted own comment to use FIP antivirals from the black market, which provides more detailed information on current use strategies. At Whittaker Lab, we are continuing our basic research into the mechanisms that coronaviruses use to expand their cellular tropism in order to better understand the factors that lead to diseases such as FIP and COVID-19. We are committed to working in solidarity with our fellow researchers, veterinarians and cat owners to create a future without FIP.

Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

31.3.2020, Translation 25.4.2021
Tomoyoshi Doki, Masahiro Toda, Nobuhisa Hasegawa, Tsutomu Hohdatsu & Tomomi Takano
Original article: Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

Abstract

Infectious feline peritonitis (FIP) is a deadly disease of wild and domestic species of cats. Although some drugs have been shown to be effective in the treatment of FIP, they are still not available in clinical practice. In this study, we evaluated the therapeutic effect of the combined use of adalimumab (anti-human TNF-alpha monoclonal antibody, ADA) and itraconazole (ICZ), which is currently available to veterinarians. ADA neutralizing activity against fTNF-alpha-induced cytotoxicity was measured in WEHI-164 cells. Ten specific pathogen-free (SPF) cats were inoculated intraperitoneally with FIPV KU-2 type I. Cats that developed FIP were administered ADA (10 mg / animal) twice between day 0 and day 4 after the start of treatment. ICZ (50 mg / head, SID) was administered orally every day from day 0 after the start of treatment. ADA demonstrated dose-dependent neutralizing activity against rfTNF-alpha. In an animal experiment, 2 of 3 cats showed an improvement in FIP clinical symptoms and biochemistry results, an increase in peripheral blood lymphocytes, and a decrease in plasma alpha 1-AGP levels after initiation of treatment. One of the cats did not respond to treatment and was euthanized, although the level of the viral ascites gene temporarily decreased after treatment. ADA was found to have neutralizing activity against rfTNF-alpha. The combined use of ADA and ICZ has shown a therapeutic effect on experimentally induced FIP. We consider these drugs to be a treatment option until effective anti-FIPV drugs are legally available.

Introduction

Feline Infectious Peritonitis Virus (FIPV), Feline Coronavirus (FCoV) Coronaviridae, causes a deadly disease in wild and domestic cat species called feline infectious peritonitis (FIP). In cats that develop FIP, several organs are affected, including the liver, lungs, spleen, serosis, kidneys, eyes, and central nervous system, and the formation of lesions in these organs is accompanied by necrosis and pyogenic granulomatous inflammation. Accumulation of pleural effusion and ascites fluid has been reported in some cats [1].

The FCoV virion consists mainly of nucleocapsid (N), envelope (E), membrane (M) and peplomer spike (S) proteins. FCoVs are classified into two serotypes, FCoV types I and II, based on differences in the amino acid sequence of the S protein. [2, 3]. FCoV type II was generated by genomic recombination between FCoV type I and canine coronavirus II. type (CCoV) [4,5,6]. Several serological and genetic surveys have shown that type I FCoV is dominant and that most cases of FIP are caused by FIPV type I infection [7,8,9].

We have previously shown that TNF (tumor necrosis factor) -alpha plays a crucial role in the progression of FIP. TNF-alpha is overproduced by FIPV-infected macrophages. TNF-alpha is involved in lymphopenia and elevated levels of the cellular receptor FIPV serotype II, aminopeptidase N (APN) [10, 11]. Neutrophil apoptosis in cats with FIP is also reported to be inhibited by TNF-alpha [12]. This finding suggests that neutrophilia in cats with FIP is due to TNF-alpha-induced neutrophil survival. We have found that monoclonal antibody (mAb) 2-4 with high neutralizing activity against feline TNF-alpha (fTNF-alpha) is useful as a treatment for FIP [13, 14]. However, the anti-fTNF-alpha mAb has never been marketed and cannot be used clinically in animal hospitals. In human medicine, the anti-human TNF-alpha mAb is used to treat inflammatory diseases such as rheumatoid arthritis and Crohn's disease. [15]. It is commercially available and can also be used in veterinary practice. However, it is not known whether this human antibody is effective against FIP, feline disease.

Several antiviral agents have been described for the treatment of FIPV [16,17,18,19,20]. These drugs have been shown to reduce FIPV proliferation, but are not commercially distributed as veterinary drugs. We have previously found that itraconazole (ICZ), which is used in veterinary medicine, reduces the multiplication of FIPV type I [21,22,23]. However, the therapeutic effects of ICZ in cats with FIP remain unclear.

In this study, we evaluated whether adalimumab (ADA), an anti-human TNF-alpha mAb, has neutralizing activity against fTNF-alpha. We further evaluated the therapeutic effects of ADA and ICZ on FIP by administering them to cats with experimentally induced FIP.

Materials and methods

Cell cultures and viruses

WEHI-164 mouse sarcoma cells were maintained in RPMI 1640 growth medium supplemented with 10% FCS, 600 U potassium benzylpenicillin per ml, 240 μg streptomycin sulfate per ml and 50 μM 2-mercaptoethanol. WEHI-164 mouse sarcoma cells were from the American Type Culture Collection (ATCC CRL1751).

FIPV KU-2 type I was grown in whole Felis catus fetal (fcwf) -4 cells at 37 ° C. FIPV type I KU-2 type I was isolated in our laboratory.

Monoclonal antibody

Anti-fTNF-alpha mAbs 2-4 have been described in [13] and have been shown to have neutralizing activity for recombinant fTNF-alpha (rfTNF-alpha) and native fTNF-alpha. mAbs 2-4 were purified from the hybridoma culture supernatant using Protein G Sepharose (GE Healthcare Life Sciences, Marlborough, MA, USA). The anti-human TNF-alpha mAb, adalimumab (ADA, Humira®), was purchased from Eisai Co., Ltd. (Tokyo, Japan) as a 20 mg / 0.2 ml solution. ADA was diluted to a concentration of 2 mg / ml in saline.

Itraconazole

Itraconazole (ICZ) was purchased from NICHI-IKO (Toyama, Japan) and provided as a tablet (100 mg). The cats were given half a tablet, ground to a powder and mixed with food.

Neutralization of feline TNF-alpha by ADA in WEHI-164 cells

TNF-alpha neutralization in WEHI-164 cells was assayed as described by Doki et al. [13]. Briefly, WEHI-164 cells were suspended at a density of 1 × 106 cells / ml in dilution medium containing 1 μg actinomycin D (Sigma-Aldrich, St. Louis, MO, USA) per ml and preincubated at 37 ° C for 3 hours. Serially diluted mAbs were mixed with 40ng rfTNF-alpha per ml. The mixture was incubated at 37 ° C for 1 hour. Preincubated cells were seeded in a volume of 50 μl in wells of a 96-well plate. Then 50 microliters of the mixture was added to each well. After incubation at 37 ° C for 24 hours, 10 μl of WST-8 solution (WST-8 Cell Proliferation Assay Kit; Kishida Chemical Co., Ltd., Osaka, Japan) was added, and the absorbance of the formazan produced was measured at 450 nm. The percent neutralization was calculated using the following formula: Neutralization (%) = (OD wells containing mAb and rfTNF-alpha - OD wells containing rfTNF-alpha without mAb) / OD wells without mAb and rfTNF-alpha × 100.

Experiment on animals

All relevant national and institutional guidelines for the care and use of animals have been complied with. The protocol on animal experimentation was approved by the President of Kitasato University based on the decision of the Institutional Committee on the Care and Use of Animals at Kitasato University (Approval No. 18-152). Specific pathogen-free (SPF) cats were bred in our own laboratory and maintained in an isolated temperature-controlled facility.

Experimental schedule

According to the experimental schedule shown in FIG. 1, 10 SPF cats (9- or 10-month-old domestic shorthair cats) were inoculated intraperitoneally with FIPV KU-2 type I (103.6 TCID50 / ml / animal). The cats were then examined daily for clinical signs and their body temperature and weight were measured. Cats that developed FIP were administered ADA (10 mg / animal) twice intravenously between day 0 and day 4 after the start of treatment. ICZ (50 mg / animal, SID) was administered orally every day from day 0 after the start of treatment. Blood was collected from cats at weekly intervals after virus inoculation and at the time of ADA administration. Heparinized blood was used to measure complete and differential cell numbers and to isolate plasma. Plasma samples were stored at -30 ° C until the day of analysis. Cats were euthanized after reaching the human endpoint or 60 days after infection. The diagnoses of FIP were confirmed by post-mortem examination with the detection of peritoneal and pleural effusions and pyogranuloma in the main organs.

Figure 1
Experimental schedule of treatment and vaccination of FIPV cats

Measurement of plasma alpha1-glycoprotein (AGP)

AGP plasma concentrations were determined using an alpha1 AG cat plate (The Institute for Metabolic Ecosystem Lab., Osaki, Japan) according to the manufacturer's protocol.

Measurement of plasma vascular endothelial growth factor (VEGF) concentration

Plasma VEGF concentrations were determined using a human VEGF ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. The ELISA kit primarily detects feline VEGF isoform 164 [24].

Real-time quantitative RT-PCR (qRT-PCR)

To quantify viral RNA in supernatant and ascites cells, qRT-PCR was performed using a primer targeting the 3'-UTR [17]. One milliliter of ascites was collected from cat #6, and after centrifugation, the supernatant and cells were stored separately. Total RNA was isolated from the supernatant and cells from ascites using a high-purity RNA isolation kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. RNA was reverse transcribed and amplified using RNA-direct Realtime PCR Master Mix (TOYOBO, Osaka, Japan) with specific primers 3′-UTR-F (5′-GGAGGTACAAGCAACCCTATT-3′) and 3′-UTR-R (5′-GATCCAGACGTTAGCTCTTCC-3′) and a probe (FAM-5′-AGATCCGCTATGACGAGCCAACAA-3′-BHQ1). The reaction was performed in a total volume of 20 μl/well in 48-well PCR plates using the StepOne Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) at 90°C for 30 s, 60°C for 20 min, and 95°C for 1 min, followed by 45 cycles of 90°C for 15 s and 60°C for 1 min. To obtain control RNA for quantification, cDNA fragments amplified with primers 3'-UTR-F and 3'-UTR-R were cloned into pGEM-T Easy Vector (Promega, Madison, WI, USA). The linearized and purified plasmid was transcribed using the RiboMAX Large Scale RNA Production System-T7 (Promega, Madison, WI, USA) according to the manufacturer's instructions. The concentration of transcribed RNA was measured using a spectrophotometer. Tenfold dilutions of RNA transcript ranging from 1×101 up to 1 × 109 copies / μl with 10ng MS2 RNA per ml. RNA copy number was calculated according to the procedure described in Fronhoffs et al. [25]. In vitro stock solutions of transcribed RNA were stored at -80 ° C and diluted working solutions were stored at -30 ° C.

Protein sequence

The deduced amino acid sequences of feline and human TNF-alpha were obtained from RefSeq (accession numbers NP_001009835.1 and NP_000585.2). Comparison of the deduced amino acid sequences of feline and human TNF-alpha was performed using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/).

The results

Neutralizing activity of ADA against rfTNF-alpha

A comparison of the deduced amino acid sequences of feline and human TNF-alpha is shown in FIG. 2. The sequences were found to be identical to 89.7%.

Figure 2.
Amino acid sequence comparison of feline and human TNF-alpha. *: residues that interact with adalimumab

The neutralizing activity of ADA against rfTNF-alpha was measured using the WEHI-164 cytotoxicity assay. ADA neutralized rfTNF-alpha activity in a dose-dependent manner, similar to anti-fTNF-alpha mAb 2-4 (Fig. 3). The dose of mAb2-4 and ADA required to inhibit 50% cell death (IC50) was 18.1 ± 4.9 ng / ml and 36.9 ± 23.4 ng / ml, respectively.

Figure 3.
Neutralization dose-response curve against recombinant fTNF-alpha. ADA neutralizing activity against fTNF-alpha-induced cytotoxicity was measured in WEHI-164 cells. WEHI-164 cells were treated with mixtures of serial dilutions of ADA and fTNF-alpha and the level of TNF-alpha-induced cytotoxicity was measured after 24 hours.

Changes in body temperature and body weight

Ten SPF cats were inoculated intraperitoneally with 103.6 TCID50 FIPV KU-2 type I. Three cats (2, 3 and 6) showed fever, anorexia, lethargy and jaundice. Abdominal distension caused by ascites was observed in cat no. 6. These 3 cats were used in the following experiments as FIP cats. Treatment for cats 2, 3 and 6 was started on days 34, 32 and 21 after virus vaccination.

The changes in body temperature and body weight of the three cats are shown in FIG. 4. All developed fever ≥ 39 ° C several days before treatment (Fig. 4A). In cats 2 and 3, body temperature decreased to a pre-FIP range on day 7 after the start of treatment. Then the body temperature of cat no. 3 increased to 38.7 ° C on day 31 after the start of treatment. Cat body temperature no. 6 remained at ≥ 39.0 ° C even after the start of treatment.

Figure 4.
Changes in body temperature and weight of cats. †: The cat was euthanized because its clinical condition reached a human endpoint

In cats 2 and 3, no weight loss was observed compared to body weight on day 0 of treatment (Fig. 4B). Body weight of cat no. 6 continued to decrease from day 0 to day 15, resulting in a 8% loss compared to day 0.

Changes in WBC and lymphocyte counts

Total white blood cell and lymphocyte counts were measured in FIPV-infected cats. Cats 2 and 3 showed a small change in total white blood cell count throughout the experiment (Fig. 5A). In cat no. 6, the total white blood cell count increased after the start of treatment and remained at ≥ 20,000 cells / μl after day 6.

Figure 5.
Changes in WBC and lymphocyte counts in cats. †: The cat was euthanized because its clinical condition reached a human endpoint

In cats 2 and 3, the number of lymphocytes increased slightly after the start of treatment (Fig. 5B). In cat no. 6, the lymphocyte count remained low throughout the experiment. It decreased to approximately 800 cells / μl on day 6 after the start of treatment, but recovered to near pre-FIP levels on day 13 and did not show a significant change up to the human endpoint.

Changes in alpha1-acid glycoprotein (AGP) plasma concentrations

Plasma alpha 1-AGP levels were measured sequentially in three cats. In all three cats, it increased to a high level ≥ 750 μg / ml at the start of treatment (Fig. 6). In cats 2 and 3, plasma alpha 1-AGP levels decreased to near pre-FIP levels on days 14 and 16 after treatment. However, in cat no. 6, the increase in plasma alpha 1-AGP levels was suppressed until day 6 after the start of treatment, but increased to approximately 1,900 μg / ml on day 13.

Figure 6.
Changes in plasma alpha1-acid glycoprotein (AGP) levels in cats. †: The cat was euthanized because its clinical condition reached a human endpoint

Changes in plasma vascular endothelial growth factor (VEGF) concentration

Plasma VEGF levels were measured sequentially in three cats. In cat no. 2 remained low (FIG. 7). In cat no. 3, increased temporarily to approximately 200 pg / ml on day 5 before treatment, but decreased to near pre-FIP levels on day 0 of treatment and showed no increase after treatment. In cat no. 6, plasma VEGF levels increased to approximately 170 pg / ml after FIPV inoculation on day 0 of treatment. It then decreased from day 6 of treatment and was similar to the level before the onset of FIP on day 13.

Figure 7.
Changes in plasma vascular endothelial growth factor (VEGF) levels in cats. †: The cat was euthanized because its clinical condition reached a human endpoint

Levels of viral RNA in supernatant and ascites cells in cat no. 6

Levels of viral RNA in the supernatant and ascites cells collected from cat no. 6 were quantified by qRT-PCR. The level of viral RNA temporarily decreased on day 4 after the start of treatment in the supernatant and in the ascites cells (Fig. 8). However, on day 20 after the start of treatment, viral RNA levels in the supernatant and ascites cells doubled on day 0 of treatment.

Figure 8.
Levels of viral RNA in the supernatant and ascites cells collected from cat no. 6 were quantified by qRT-PCR. The level of viral RNA temporarily decreased on day 4 after the start of treatment in the supernatant and in the ascites cells (Fig. 8). However, on day 20 after the start of treatment, viral RNA levels in the supernatant and ascites cells doubled on day 0 of treatment.

Biochemical panel

After treatment, TP and A / G ratio, which are diagnostic indices of FIP, and AST, LDH, and TB, which are related to liver function, were measured (Fig. 9). TP increased slightly in cat no. 3, but remained within the normal range for all three cats. On the other hand, the A / G ratio decreased after FIPV exposure in all three cats and was ≤ 0.8 on day 0 of treatment. In cat no. 2, the A / G ratio remained similar to that after the start of treatment until the end of the experiment. In cat no. 3, decreased until day 16 of treatment, but then showed no further decrease. In cat no. 6 the decrease continued even after the start of treatment.

Figure 9.
Biochemical panel. The white areas of the graphs represent normal ranges. †: The cat was euthanized because its clinical condition reached a human endpoint

AST, LDH and TB were higher than the normal range on day 0 or 3 of treatment in all three cats. In cats 2 and 3, AST, LDH and TB decreased to near pre-FIP levels on day 7 or 9 after treatment. In cat no. 6, AST, LDH and TB were higher than the normal range on day 0 or 4 after the start of treatment and continued to increase until the end of the experiment.

Discussion

A strong therapeutic effect can be achieved when cats with FIP are administered an anti-fTNF-alpha mAb, which suppresses TNF-alpha activity, a FIP exacerbator, in combination with ICZ, which reduces FIPV proliferation. However, approving an anti-fTNF-alpha mAb as a veterinary drug in each country is costly and time consuming. Therefore, we focused on the anti-human TNF-alpha mAb, which is already used to treat human inflammatory diseases.

Prior to animal experiments, we investigated whether the anti-human TNF-alpha mAb could neutralize fTNF-alpha. ADA, an anti-human TNF-alpha mAb, demonstrated dose-dependent neutralizing activity against rfTNF-alpha, similar to anti-fTNF-alpha mAb 2-4. The nine previously reported anti-fTNF-alpha mAbs had IC50s ranging from 5 to 700 ng / ml against rfTNF-alpha at the same concentration [13]. The IC50 of ADA (36.9 ± 23.4 ng / ml) indicates that it has a high neutralizing activity against fTNF-alpha compared to these anti-fTNF-alpha mAbs. As a rule, anti-human cytokine mAbs do not show any cross-reactive neutralizing activity against animal cytokines. However, Aguirre et al. reported that human and feline TNF-alpha have similar neutralizing epitopes [26]. In addition, the deduced amino acid sequence of human TNF-alpha at 89.7% is identical to that of feline TNF-alpha, and both have 10 of the 12 residues that interact with ADA. [27]. This appears to be the reason for the strong neutralizing activity of adalimumab against feline TNF-alpha.

We administered ADA and ICZ to cats with experimentally induced FIP and investigated their therapeutic effect. Of the 10 SPF cats that received intraperitoneally administered FIPV KU-2 type I, three developed FIP. Of these three cats, cat no. 6 had apparent ascites. These three cats were considered to have developed FIP for the following reasons: (i) all three cats were infected with FIPV, (ii) clinical signs associated with FIP were observed, (iii) elevated plasma alpha-1 levels of AGP and VEGF, and (iv) as a reference data from our previous animal experiments were used. ADA (10 mg / animal) was administered intravenously to three cats on day 0 and within 4 days after the start of treatment. In addition, ICZ (50 mg / animal) was administered orally every day, starting on day 0 of treatment. In cats 2 and 3, an improvement in clinical signs and blood test results, an increase in peripheral blood lymphocytes and a decrease in plasma alpha 1-AGP levels were observed after initiation of treatment. Symptomatic improvements were observed between weeks 1 and 2 after the start of treatment. Furthermore, no ascites or pyogenic granulomas were pathologically observed in cats 2 and 3 at the end of the experiment, and no changes suggestive of recurrence of FIP were observed by the end of the treatment period. Cat no. 6 did not respond to treatment and was euthanized, although the level of the viral ascites gene temporarily decreased after the start of treatment. These results strongly suggest that anti-human TNF-alpha mAbs and ICZs are effective in the treatment of FIP.

VEGF is produced by FIPV-infected macrophages and improves feline endothelial cell permeability [28]. In cats with FIP, plasma VEGF levels correlate with ascites. Cat no. 6, in whom ascites was evident on both preliminary and palpation examinations (160 ml of ascites was obtained by euthanasia), had a high plasma VEGF level ≥100 pg / ml for 3 weeks. However, in cats 2 and 3, which showed no signs of ascites, plasma VEGF levels remained low or increased only temporarily. Thus, plasma VEGF levels were confirmed to correlate with the amount of ascites in cats with FIP.

Azole antifungal agents, including ICZ, are known to have hepatotoxicity as a side effect and are likely to cause cholestasis and jaundice. [29,30,31,32]. Because an increase in liver enzymes is observed in cats with FIP, the development of side effects after ICZ administration would be worrying. However, in cats 2 and 3, liver marker markers, which increased during treatment, returned to normal and the plasma jaundice disappeared. Therefore, no adverse effects of ICZ have been reported. Therefore, in terms of side effects, ICZ administration is considered safe for FIP cats.

Recently, GC-376, a 3C-like protease inhibitor, and GS-441524, a nucleoside analog, have been developed as drugs to inhibit FIPV proliferation. [16,17,18,19,20]. GC-376 and GS-441524 are effective drugs that have therapeutic effects in 30-80% cats with FIP. Although these drugs are expected to be useful in the treatment of FIP, they have not yet been approved. Therefore, no drugs are available in clinical practice to treat FIP. In this study, we demonstrated that the combined use of ADA and ICZ, which is currently available to veterinarians, is effective in the treatment of FIP. We consider these drugs to be a treatment option until antiviral drugs such as GC-376 and GS-441524 become available. In addition, these antiviral drugs have therapeutic effects on FIP by mechanisms different from ADA and ICZ [16, 18, 21, 23]. In the future, evaluating the therapeutic effects of their current use may help to develop a more effective treatment for FIP.

Conclusions

The therapeutic effects of adalimumab, anti-human TNF-alpha mAb and itraconazole on FIP were investigated. Adalimumab was found to have neutralizing activity against rfTNF-alpha, similar to anti-fTNF-alpha mAbs. FIP was successfully treated in 2 of 3 cats with experimentally induced FIP by adalimumab and itraconazole.

References

  1. Pedersen NC (2014) An update on feline infectious peritonitis: diagnostics and therapeutics. Vet J 201: 133–141. https://doi.org/10.1016/j.tvjl.2014.04.016Article PubMed Google Scholar 
  2. Tekes G, Thiel HJ (2016) Feline coronaviruses: pathogenesis of feline infectious peritonitis. In: Ziebuhr J (ed) Advances in virus research, vol. 96, Academic Press, pp 193–218
  3. Jaimes JA, Whittaker GR (2018) Feline coronavirus: insights into viral pathogenesis based on the spike protein structure and function. Virology 517: 108–121. https://doi.org/10.1016/j.virol.2017.12.027TIME Article PubMed Google Scholar 
  4. Decaro N, Mari V, Campolo M et al (2009) Recombinant canine coronaviruses related to transmissible gastroenteritis virus of swine are circulating in dogs. J Virol 83: 1532–1537. https://doi.org/10.1128/jvi.01937-08TIME Article PubMed Google Scholar 
  5. Herrewegh AA, Smeenk I, Horzinek MC et al (1998) Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol 72: 4508–4514TIME Article PubMed Google Scholar 
  6. Terada Y, Shiozaki Y, Shimoda H et al (2012) Feline infectious peritonitis virus with a large deletion in the 59-terminal region of the spike gene retains its virulence for cats. J Gen Virol 93: 1930–1934. https://doi.org/10.1099/vir.0.043992-0TIME Article PubMed Google Scholar 
  7. Addie DD, Schaap IAT, Nicolson L, Jarrett O (2003) Persistence and transmission of natural type I feline coronavirus infection. J Gen Virol 84: 2735–2744. https://doi.org/10.1099/vir.0.19129-0TIME Article PubMed Google Scholar 
  8. Kummrow M, Meli ML, Haessig M et al (2005) Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol 12: 1209–1215. https://doi.org/10.1128/CDLI.12.10.1209-1215.2005TIME Article PubMed Google Scholar 
  9. Hohdatsu T, Okada S, Ishizuka Y et al (1992) The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci 54: 557–562. https://doi.org/10.1292/jvms.54.557TIME Article PubMed Google Scholar 
  10. Takano T, Hohdatsu T, Hashida Y et al (2007) A “possible” involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Vet Microbiol 119: 121–131. https://doi.org/10.1016/j.vetmic.2006.08.033TIME Article PubMed Google Scholar 
  11. Takano T, Hohdatsu T, Toda A et al (2007) TNF-alpha, produced by feline infectious peritonitis virus (FIPV) -infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 364: 64–72. https://doi.org/10.1016/j.virol.2007.02.006TIME Article PubMed Google Scholar 
  12. Takano T, Azuma N, Satoh M et al (2009) Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages in cats infected with feline infectious peritonitis virus contribute to the pathogenesis of granulomatous lesions. Arch Virol 154: 775–781. https://doi.org/10.1007/s00705-009-0371-3TIME Article PubMed Google Scholar 
  13. Doki T, Takano T, Nishiyama Y et al (2013) Generation, characterization and therapeutic potential of anti-feline TNF-alpha MAbs for feline infectious peritonitis. Res Vet Sci 95: 1248–1254. https://doi.org/10.1016/j.rvsc.2013.09.005TIME Article PubMed Google Scholar 
  14. Doki T, Takano T, Kawagoe K et al (2016) Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis. Res Vet Sci 104: 17–23. https://doi.org/10.1016/j.rvsc.2015.11.005TIME Article PubMed Google Scholar 
  15. Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244–279TIME Article PubMed Google Scholar 
  16. Kim Y, Lovell S, Tiew KC et al (2012) Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 86: 11754–11762. https://doi.org/10.1128/JVI.01348-12TIME Article PubMed Google Scholar 
  17. Kim Y, Liu H, Galasiti Kankanamalage AC et al (2016) Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog 12: e1005531. https://doi.org/10.1371/journal.ppat.1005531TIME Article PubMed Google Scholar 
  18. Murphy BG, Perron M, Murakami E et al (2018) The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol 219: 226–233. https://doi.org/10.1016/j.vetmic.2018.04.026TIME Article PubMed Google Scholar 
  19. Pedersen NC, Kim Y, Liu H et al (2018) Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg 20: 378–392. https://doi.org/10.1177/1098612X17729626Article PubMed Google Scholar 
  20. Pedersen NC, Perron M, Bannasch M et al (2019) Efficacy and safety of the nucleoside analog GS-441524 for the treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg 21: 271–281. https://doi.org/10.1177/1098612X19825701Article PubMed Google Scholar 
  21. Takano T, Akiyama M, Doki T, Hohdatsu T (2019) Antiviral activity of itraconazole against type I feline coronavirus infection. Vet Res 50: 5. https://doi.org/10.1186/s13567-019-0625-3Article PubMed Google Scholar 
  22. Takano T, Endoh M, Fukatsu H et al (2017) The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection. Antivir Res 145: 96–102. https://doi.org/10.1016/j.antiviral.2017.07.022TIME Article PubMed Google Scholar 
  23. Takano T, Wakayama Y, Doki T (2019) Endocytic pathway of feline coronavirus for cell entry: differences in serotype-dependent viral entry pathway. Pathogens 8: 300. https://doi.org/10.3390/pathogens8040300TIME Article Google Scholar 
  24. Koga L, Kobayashi Y, Yazawa M et al (2002) Nucleotide sequence and expression of the feline vascular endothelial growth factor. J Vet Med Sci 64: 453–456. https://doi.org/10.1292/jvms.64.453TIME Article PubMed Google Scholar 
  25. Fronhoffs S, Totzke G, Stier S et al (2002) A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction. Mol Cell Probes 16: 99–110. https://doi.org/10.1006/mcpr.2002.0405TIME Article PubMed Google Scholar 
  26. Aguirre A, Escobar A, Ferreira V et al (2003) An anti-human recombinant tumor necrosis factor alpha (TNFα) monoclonal antibody recognizes an epitope in the TNFα feline. Vet Res 34: 177–184. https://doi.org/10.1051/vetres:2002064TIME Article PubMed Google Scholar 
  27. Hu S, Liang S, Guo H et al (2013) Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 288: 27059–27067. https://doi.org/10.1074/jbc.M113.491530TIME Article PubMed Google Scholar 
  28. Takano T, Ohyama T, Kokumoto A et al (2011) Vascular endothelial growth factor (VEGF), produced by feline infectious peritonitis (FIP) virus-infected monocytes and macrophages, vascular permeability induces and effusion in cats with FIP. Virus Res 158: 161–168. https://doi.org/10.1016/j.virusres.2011.03.027TIME Article PubMed Google Scholar 
  29. García Rodrǐguez LA, Duque A, Castellsague J et al (1999) A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48: 847–852. https://doi.org/10.1046/j.1365-2125.1999.00095.xArticle PubMed Google Scholar 
  30. Kao WY, Su CW, Huang YS et al (2014) Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol 77: 180–189. https://doi.org/10.1111/bcp.12178TIME Article PubMed Google Scholar 
  31. Susan M, Grant SPC (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344Article Google Scholar 
  32. Khoza S, Moyo I, Ncube D (2017) Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats. J Toxicol. https://doi.org/10.1155/2017/6746989Article PubMed Google Scholar 

Thanks

We thank the members of our laboratory for supporting animal experiments. This work was partially supported by KAKENHI (Grants-in-Aid for Scientific Research (B), No. 16H05039) from the Ministry of Education, Culture, Sports, Science and Technology in Japan and the Kitasato University Research Grants for Kitasato University Young Scientists.

Ethical statements

Conflict of interests

The authors are not aware of any potential conflicts of interest in connection with the research, authorship or publication of this article.

Ethical approval

All relevant national and institutional guidelines for the care and use of animals have been complied with. The protocol on animal experimentation was approved by the President of Kitasato University based on the decision of the Institutional Committee on the Care and Use of Animals at Kitasato University (Approval No. 18-152). SPF cats were bred in our own laboratory and maintained in an isolated temperature-controlled facility. Sample sizes were determined based on our experience with FIPV infection models and a minimum number of cats were used.

Informed consent

Informed consent was obtained from the legal guardian of all experimental animals described in this work for the procedures performed. No animals or humans are identifiable in this publication and therefore no further informed consent to the publication was required.

More details

Publisher Note

Springer Nature remains neutral in terms of jurisdictional claims in published maps and institutional links.

Editor: Sheela Ramamoorthy.

Possible Antiviral Activity of 5-Aminolevulinic Acid in Feline Infectious Peritonitis Virus (Feline Coronavirus) Infection

Tomomi Takano, Kumi Satoh, and Tomoyoshi Doki
Original article: Possible Antiviral Activity of 5-Aminolevulinic Acid in Feline Infectious Peritonitis Virus (Feline Coronavirus) Infection; 10.2.2021; 18.4.2021

Abstract

Infectious feline peritonitis (FIP) is a life-threatening infectious disease of cats caused by virulent feline coronavirus (FIP: FIPV). Several effective antivirals have recently emerged for the treatment of FIP, but many are not available for practical use. 5-Aminolevulinic acid (5-ALA) is a low molecular weight amino acid synthesized in plant and animal cells. 5-ALA can be synthesized in large quantities and is widely used in the medical and agricultural industries. We hypothesized that 5-ALA inhibits FIPV infection. Therefore, we evaluated its antiviral activity against FIPV in whole felis catus fetal 4 cells and in primary feline macrophages. FIPV infection was significantly inhibited by 250 μM 5-ALA. Our study suggested that 5-ALA is useful for the treatment and prevention of FIPV infection.

Keywords: FIP, coronavirus, 5-aminolevulinic acid, antiviral drug, cat

Introduction

Feline Infectious Peritonitis (FIP) is a life-threatening infectious disease caused by feline coronavirus (FCoV) in domestic and wild Felidae species. FCoV is highly prevalent in cats throughout the world. FCoV is an enveloped single-stranded positive RNA virus. This virus belongs to the genus Alphacoronavirus of the subfamily Orthocoronavirinae of the family Coronaviridae (1). FCoV is divided into two serotypes according to the amino acid sequence of the spike protein (S), FCoV serotype I and FCoV serotype II (2). Serological and genetic studies have revealed that type I FCoV is dominant worldwide (3-5). FCoV is spread mainly by faecal-oral transmission (6). Most FCoV-infected cats are subclinical. However, several mutations have occurred in the VS protein that have led to the development of a virulent type called feline infectious peritonitis virus (FIPV) (7, 8). Serum in the peritoneal and pleural cavities and pyogranulomatous lesions in several organs are characteristic pathological findings of FIP in cats (9).

FIP is an immune-mediated and difficult-to-treat viral infection. Several effective antivirals for the treatment of FIP have recently been published (10, 11), but many are not available for practical use. Some anti-FCoV drugs, such as itraconazole, are available in animal kinetics, but their therapeutic effects are limited (12). Because FIP is a chronic and systemic disease, clinical remission is difficult to achieve. Therefore, it is desirable that therapeutic drugs for FIP have the following properties: (1) Few side effects for cats, (2) low cost, and (3) low pathogen mutagenesis.

5-Aminolevulinic acid (5-ALA) is a low molecular weight amino acid synthesized in plant and animal cells (13, 14). It is an intermediate in tetrapyrrole biosynthesis. Because 5-ALA is highly soluble in water and has low cytotoxicity, it is widely used in the medical and agricultural industries (15). Several studies have been published on the effects of 5-ALA on infectious diseases. Suzuki et al. stated that when 5-ALA and iron ion were administered orally to mice infected with a malaria parasite (Plasmodium yoelii), the mice survived (16). On the other hand, its effects on viral infection are unclear.

In veterinary medicine, photodynamic therapy (PDT) using 5-ALA has been studied in the treatment of tumors in dogs (17), but to our knowledge the effect of 5-ALA on infectious animal diseases has not been studied. We investigated whether 5-ALA could be administered as an anti-FCoV drug in vitro.

Materials and methods

Cell cultures, animals and viruses

Feline fetal 4-cell Felis catus (fcwf)-4 (kindly provided by Dr. MC Horzinke from Utrecht University) were grown in Eagles’ MEM containing 50% of Leibovitz’s L-15 medium, 5% of fetal calf serum (FCS), 100 U/ml penicillin and 100 μg/ml streptomycin. The maintenance medium had the same composition as the growth medium except for the FCS concentration (2%). Feline primary macrophages were selected for primary macrophages. Feline alveolar macrophages were obtained from four specific pathogen-free (SPF) cats aged 3–5 years by bronchoalveolar lavage with Hank’s balanced salt solution. Feline primary macrophages were maintained in D-MEM supplemented with 10% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin. SPF cats were maintained in an isolated, temperature-controlled facility. The animal experiment was approved by the President of Kitasato University based on the decision of the Institutional Animal Care and Use Committee of Kitasato University (18-050) and performed in accordance with the Guidelines for Animal Experiments of Kitasato University. Sample sizes were determined based on our previous study and a minimum number of cats were used. The FCoV KU-2 type I strain (FIPV-I KU-2) was isolated in our laboratory. FCoV-II 79-1146 was kindly provided by Dr. MC Horzinek from Utrecht University. These viruses were cultured in fcwf-4 cells at 37°C.

Compounds

5-ALA and sodium ferrous citrate (SFC) were provided by Neopharma Japan (Tokyo, Japan). 5-ALA and SFC were dissolved in culture medium at 200 mM and 50 mM. The SFC solution was used as the 5-ALA solvent. On the day of the experiments, these compounds were diluted to the desired concentrations in the culture medium.

Cytotoxic effects of compounds

Fcwf-4 cells were seeded in 96-well plates. Compounds were loaded into wells in triplicate. After incubation for 96 hours, the culture supernatants were removed, WST-8 solution (Kishida Chemical, Osaka, Japan) was added, and the cells were returned to the incubator for 1 hour. The absorbance of the formazan produced was measured at 450 nm using a 96-well spectrophotometric plate reader, according to the manufacturer's recommendations. Percent cell viability was calculated using the following formula: Cell viability (%) = [(OD of untreated compounds - cells treated with compound) / (OD of cells not treated with compound)] x100. 50% cytotoxicity concentration (CC50 ) was defined as the cytotoxic concentration of each compound that reduced the absorbance of treated cells to 50% compared to the absorption of untreated cells.

Antiviral effects of 5-ALA

Confluent monolayers of fcwf-4 cells were cultured in or without compound media at the indicated concentrations in 24-well multi-plate plates at 37 ° C for 24 or 48 hours. The cells were washed and the virus (MOI 0.01) was adsorbed into the cells at 37 ° C for 1 hour. After washing, cells were cultured in 1.5% carboxymethylcellulose (CMC) -MEM or MEM with or without compounds. For cells cultured in CMC-MEM, cell monolayers were incubated at 37 ° C for 48 hours, fixed and stained with 1% crystal violet solution containing 10% buffered formalin, and then the resulting plaques were counted. The percentage of decrease or increase in plaques was calculated using the following formula: Percent reduction of plaques (%) = [(number of plaques of compounds treated with compound) / (number of plaques of cells not treated with compound)] x100. EC50 was defined as the effective concentration of compounds that reduced the virus titer in the culture supernatant of infected cells to 50% compared to the virus control titer. For cells cultured in MEM, culture supernatants were collected 48 hours after infection and virus titers were measured by TCID assay.50.

Primary feline macrophages were cultured in medium with or without compounds at the indicated concentrations in 24-well multiple plates at 37 ° C for 48 hours. After washing with PBS, FIPV 79-1146 (1 x 104 TCID50) adsorbed into cells at 37 ° C with 5% CO2 for 1 hour. After washing with PBS, the cells were cultured in medium and the supernatants were collected. Virus titers were measured using the TCID assay50.

Statistical analysis

Data from only two groups were analyzed using Student's t-test (Welch t-test) and data from multiple groups were analyzed by one-way ANOVA followed by Tukey's test. A P value <0.05 was considered significant.

The results

Cytotoxic and antiviral effects of 5-ALA

A cytotoxicity assay was performed to determine the non-toxic concentration of 5-ALA against fcwf-4 cells (Figure 1). More than 75% fcwf-4 cells survived in the presence of 1,000 μM 5-ALA (maximum concentration in this experiment). The vehicle does not show any cytotoxic effects on fcwf-4 cells.

Figure 1.

Cytotoxic effects of 5-ALA on fcwf-4 cells. The viability of fcwf-4 cells was measured using the WST-8 assay. Black ring: 5-ALA. White circle: Vehicle (SFC). The vehicle (control solvent) was the same as the vehicle in the 5-ALA solution at each serial dilution. Results are presented as mean ± SE. The data represent three independent experiments (n = 3).

Effects of 5-ALA on FIPV infection in a feline cell line

The antiviral effects of 5-ALA against FIPV were evaluated in a plaque inhibition assay in fcwf-4 cells. Cells were treated with 5-ALA as follows: 24-hour pre-treatment (pre-24h), 24-hour pre-treatment followed by 49-hour FIPV treatment (pre-24h and co-49h) and 48-hour pre-treatment, after which followed by a 49-hour FIPV treatment (pre-48h and co-49h). At pre-24h, the percent plaque inhibition increased significantly at 500 μM or higher (Figures 2A, B). At pre-24h and co-49h, the percentage of plaque inhibition increased significantly at 125μM or higher (Figures 2C, D). At pre-48h and co-49h, the percentage of plaque inhibition in FIPV type I reached 125 μM 5-ALA 75% (Figures 2E, F). The control vehicle, SFC, showed no plaque inhibitory effects on FCoV under any conditions. According to the titration assay, FIPV type I and type II production was significantly reduced at 250 and 500 μM 5-ALA (Figure 3).

Figure 2.
FIPV plaque inhibition assay in 5-ALA-treated fcwf-4 cells. (A, B) Effects of 24-hour pretreatment on 5-ALA antiviral activity. Plaque inhibition rate of FIPV-infected fcwf-4 cells pretreated with 5-ALA for 24 hours. (C, D) Effects of 24-hour pre-treatment and 48-hour post-treatment on 5-ALA antiviral activity. Plaque inhibition rate of FIPV-infected fcwf-4 cells pre-treated for 24 hours and post-treated for 48 hours with 5-ALA. (E, F) Effects of 48-hour pre-treatment and 48-hour post-treatment on 5-ALA antiviral activity. Plaque inhibition rate of FIPV-infected fcwf-4 cells pretreated for 48 hours followed by 5-ALA for 48 hours. (A, C, E) type I FIPV. (B, D, F) type II FIPV. Black column: 5-ALA. White column: Vehicle (control solvent). Results are presented as mean ± SE. The data represent four independent experiments (n = 4). ** p <0.01 (* p <0.05) vs. vehicle.
Figure 3.
Inhibition of FIPV 5-ALA infection in fcwf-4 cells. (A, C) Effects of 48-hour pre-treatment and 48-hour post-treatment on antiviral activity of 250 μM 5-ALA. (B, D) Effects of 48-hour pre-treatment and 48-hour post-treatment on the antiviral activity of 500 μM 5-ALA. (A, B) 250 μM 5-ALA. (A, B) type I FIPV. (C, D) type II FIPV. Black ring: 5-ALA. White circle: vehicle (control solvent). Results are presented as mean ± SE. The data represent four independent experiments (n = 4). ** p <0.01 (* p <0.05) vs. vehicle.

Effects of 5-ALA on FIPV infection in a feline cell line

FIPV-infected macrophages are involved in the progression of FIP symptoms to severe. We investigated whether 5-ALA inhibits FIPV proliferation in macrophages. In this experiment, FIPV 79-1146 type II with a high ability to reproduce in primary cat macrophages was used. Virus production in FIPV-infected macrophages was reduced at 250 μM 5-ALA in three of the four cats (Figure 4).

Figure 4.
Inhibition of FIPV infection in macrophages. Effects on 5-ALA antiviral activity (250μM) in primary cat macrophages. Black column: 5-ALA. White column: Vehicle (control solvent). The data represent three independent experiments (n = 3).

Discussion

5-ALA is an intermediate in the synthesis of tetrapyrrole in animals, plants and microorganisms (13-15). The potential for 5-ALA efficacy in plants was reported in the 1980s (18), but it was difficult to produce 5-ALA in sufficient quantities for practical use because only a small amount is produced in microorganisms. After Nishikawa et al. introduced the method of mass production of 5-ALA using bacteria (19), the effectiveness of 5-ALA has been confirmed not only in agriculture but also in the medical and biological fields. 5-ALA is an inexpensive drug and is practically used as a supplement to improve animal performance and immune response in veterinary medicine (14, 20).

5-ALA inhibited FIPV growth in fcwf-4 cells. The metal complexes of the 5-ALA metabolite, protoporphyrin IX (PpIX), were found to have antiviral activity (21-23). The PpIX metal complex, heme, inhibits the multiplication of dengue virus (21). On the other hand, the multiplication of Zika virus is not inhibited by heme (23). It is not clear whether heme inhibits FCoV proliferation. Generally, an increase in intracellular heme stimulates the production of hemeoxygenase-1 (HO-1), a heme degrading enzyme. HO-1 has been reported to induce antiviral activity (24, 25). However, in a preliminary experiment, we confirmed that the expression level of HO-1 mRNA in cells treated with 250μM 5-ALA remained unchanged (data not shown). Based on this finding, 5-ALA-induced inhibition of FIPV infection occurs due to a factor other than heme and HO-1.

There are already many studies on therapeutic drugs in FIP. Many drugs effective in FIP have been identified in vitro, and some have been shown to have therapeutic effects when administered to cats with FIP (10-12). However, the effects of all drugs were weak in cases with neurological manifestations. Poor transmission of these drugs to the central nervous system was thought to be the cause; therefore, there is a need for a drug that has antiviral effects against FIPV capable of entering brain tissue. 5-ALA is an amino acid with low molecular weight and possible good penetration ability into brain tissue (26). It is further reported that the diffusion of 5-ALA from the blood into normal brain tissue is very low (27), suggesting that it has fewer adverse effects. FIP can only be unambiguously diagnosed by detecting the FCoV antigen in the lesion (28). However, when treatment is not started until a clear diagnosis has been made, the symptoms have meanwhile progressed to a state where, in many cases, there is no longer a response to treatment. Therefore, if there is a drug that can be given prophylactically before the diagnosis of FIP, it is possible to prevent the progression of symptoms, for which 5-ALA may be an ideal means. However, in our experiment with FIPV target cells, macrophages, the antiviral effects of 5-ALA were not observed in some cats. Therefore, when 5-ALA is used as a therapeutic drug for FIP, anti-FCoV drugs such as GS-441524 (29), GC-376 (30), U18666A (31) and itraconazole (32) or anti-inflammatory drugs such as anti-TNF-alpha antibody (33) should be used concomitantly.

FECV transmission mainly occurs in cats in the field, while horizontal FIPV infection between cats is considered rare (34). FIPV has been found to be generated by a genetic mutation of FECV. Thus, if there are means to prevent FECV infection on a daily basis, the development of FIP can be prevented. No vaccine has been developed to prevent FECV infection. Addie et al. reported that viral gene secretion in faeces ceased in FECV-infected cats treated with a synthetic adenosine analog (35). Therefore, elimination of FECV infecting the gut is expected by administering FECV antivirals to infected cats. However, synthetic adenosine analogs can induce coronavirus gene mutations (36). In addition, although the level of the FECV gene in feces has fallen below the limit of detection in cats treated with a synthetic adenosine analog, it is possible that FECV has latently infected the gut or other tissues. Long-term administration of a synthetic adenosine analog is required to prevent FECV gene mutation and reliably eliminate FECV infection, but this is not realistic due to its high cost. On the other hand, 5-ALA is practically used as a dietary supplement. 5-ALA has low toxicity to animals and plants, which strongly suggests the possibility of long-term administration of 5-ALA to cats. In the future, it is necessary to examine whether 5-ALA is useful as an adjunct to prevent the development of FIP in cats infected with FECV.

In this study, we confirmed the possibility that 5-ALA inhibits FIPV proliferation and TNF-alpha production. Because 5-ALA is an amino acid present in the body, immediate administration is possible. However, it is necessary to administer 5-ALA to cats with FIP and to monitor whether therapeutic effects can be achieved. It is further investigated whether long-term administration of 5-ALA eliminates the virus and inhibits FIP development in FECV-infected cats.

References

  1. ICTV Coronaviridae. Virus Taxonomy: 2019 Release. (2020). Available online at: https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/222/coronaviridae (accessed December 25, 2020).
  2. Motokawa K, Hohdatsu T, Aizawa C, Koyama H, Hashimoto H. Molecular cloning and sequence determination of the peplomer protein gene of feline infectious peritonitis virus type I. Arch Virol. (1995) 140: 469–80. 10.1007 / BF01718424 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  3. Hohdatsu T, Okada S, Ishizuka Y, Yamada H, Koyama H. The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci. (1992) 54: 557–62. 10.1292 / jvms.54.557 [PubMed] [CrossRef] [Google Scholar]
  4. Kummrow M, Meli ML, Haessig M, Goenczi E, Poland A, Pedersen NC, et al. . (2005). Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol. 12: 1209–15. 10.1128 / CDLI.12.10.1209-1215.2005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  5. Wang YT, Chueh LL, Wan CH. An 8-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections. BMC Vet Res. (2014) 10: 186 10.1186 / s12917-014-0186-7 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  6. Pedersen NC. An overview of feline enteric coronavirus and infectious peritonitis virus infections. Feline Pract. (1995) 23: 7-21. [Google Scholar]
  7. Chang HW, Egberink HF, Halpin R, Spiro DJ, Rottier PJ. Spike protein fusion peptide and feline coronavirus virulence. Emerg Infect Dis. (2012) 18: 1089. 10.3201 / eid1807.120143 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  8. Licitra BN, Millet JK, Regan AD, Hamilton BS, Rinaldi VD, Duhamel GE, et al. . Mutation in spike protein cleavage site and pathogenesis of feline coronavirus. Emerg Infect Dis. (2013) 19: 1066. 10.3201 / eid1907.121094 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  9. Tekes G, Thiel HJ. Feline coronaviruses: pathogenesis of feline infectious peritonitis. Adv Virus Res. (2016) 96: 193–218. 10.1016 / bs.aivir.2016.08.002 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  10. Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, et al. . Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg. (2018) 20: 378–92. 10.1177 / 1098612X17729626 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  11. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, et al. . Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. (2019) 21: 271–81. 10.1177 / 1098612X19825701 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  12. Kameshima S, Kimura Y, Doki T, Takano T, Park CH, Itoh N. Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis. J Vet Med Sci. (2020) 82: 1492–6. 10.1292 / jvms.20-0049 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  13. Czarnecki O, Grimm B. New insights in the topology of the biosynthesis of 5-aminolevulinic acid. Plant Signal Behav. (2013) 8: e23124. 10.4161 / psb.23124 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  14. Hendawy AO, Khattab MS, Sugimura S, Sato K. Effects of 5-aminolevulinic acid as a supplement on animal performance, iron status, and immune response in farm animals: a review. Animals. (2020) 10: 1352. 10.3390 / ani10081352 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  15. Sasaki K, Watanabe M, Tanaka T, Tanaka T. Biosynthesis, biotechnological production and applications of 5-aminolevulinic acid. Appl Microbiol Biotechnol. (2002) 58: 23–9. 10.1007 / s00253-001-0858-7 [PubMed] [CrossRef] [Google Scholar]
  16. Suzuki S, Hikosaka K, Balogun EO, Komatsuya K, Niikura M, Kobayashi F, et al. . In vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria. Antimicrob Agents Chemother. (2015) 59: 6960–7. 10.1128 / AAC.01910-15 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  17. Osaki T, Yokoe I, Ogura S, Takahashi K, Murakami K, Inoue K, et al. . Photodynamic detection of canine mammary gland tumors after oral administration of 5-aminolevulinic acid. Vet Comp Oncol. (2017) 15: 731–9. 10.1111 / vco.12213 [PubMed] [CrossRef] [Google Scholar]
  18. Rebeiz CA, Montazer-Zouhoor A, Hopen HJ, Wu SM. Photodynamic herbicides: 1. Concept and phenomenology. Enzyme Microb Technol. (1984) 6: 390-401. 10.1016 / 0141-0229 (84) 90012-7 [CrossRef] [Google Scholar]
  19. Nishikawa S, Watanabe K, Tanaka T, Miyachi N, Hotta Y, Murooka Y. Rhodobacter sphaeroides mutants which accumulate 5-aminolevulinic acid under aerobics and dark conditions. J Biosci Bioeng. (1999) 87: 798–804. 10.1016 / S1389-1723 (99) 80156-X [PubMed] [CrossRef] [Google Scholar]
  20. Sasaki A, Iwatani N, Harada K. Improvement effect of 5-aminolevulinic acid on hyperlipidemia in miniature schnauzer dogs: an open study in 5 cases of one pedigree. Yonago Acta Med. (2020) 63: 234–8. 10.33160 / yam.2020.08.006 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  21. Assunção-Miranda I, Cruz-Oliveira C, Neris RLS, Figueiredo CM, Pereira LPS, Rodrigues D, et al. . Inactivation of dengue and yellow fever viruses by heme, cobalt-protoporphyrin IX and tin-protoporphyrin IX. J Appl Microbiol. (2016) 120: 790–804. 10.1111 / jam.13038 [PubMed] [CrossRef] [Google Scholar]
  22. Cruz-Oliveira C, Almeida AF, Freire JM, Caruso MB, Morando MA, Ferreira VN, et al. . Mechanisms of vesicular stomatitis virus inactivation by protoporphyrin IX, zinc-protoporphyrin IX, and mesoporphyrin IX. Antimicrob Agents Chemother. (2017) 61: e00053-17. 10.1128 / AAC.00053-17 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  23. Neris RL, Figueiredo CM, Higa LM, Araujo DF, Carvalho CA, Verçoza BR, et al. Co-protoporphyrin IX and Sn-protoporphyrin IX inactivate Zika, Chikungunya and other arboviruses by targeting the viral envelope. Sci Rep. (2018) 8: 9805 10.1038 / s41598-018-27855-7 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  24. Espinoza JA, González PA, Kalergis AM. Modulation of antiviral immunity by heme oxygenase-1. Am J Pathol. (2017) 187: 487–93. 10.1016 / j.ajpath.2016.11.011 [PubMed] [CrossRef] [Google Scholar]
  25. Tseng CK, Lin CK, Wu YH, Chen YH, Chen WC, Young KC, et al. . Human heme oxygenase 1 is a potential host cell factor against dengue virus replication. Sci Rep. (2016) 6: 32176. 10.1038 / srep32176 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  26. Novotny A, Xiang J, Stummer W, Teuscher NS, Smith DE, Keep RF. Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J Neurochem. (2000) 75: 321–8. 10.1046 / j.1471-4159.2000.0750321.x [PubMed] [CrossRef] [Google Scholar]
  27. Ennis SR, Novotny A, Xiang J, Shakui P, Masada T, Stummer W, et al. . Transport of 5-aminolevulinic acid between blood and brain. Brain Res. (2003) 959: 226–34. 10.1016 / S0006-8993 (02) 03749-6 [PubMed] [CrossRef] [Google Scholar]
  28. Tasker S. Diagnosis of feline infectious peritonitis: update on evidence supporting available tests. J Feline Med Surg. (2018) 20: 228–43. 10.1177 / 1098612X18758592 [PubMed] [CrossRef] [Google Scholar]
  29. Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, et al. . The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. (2018) 219: 226–33. 10.1016 / j.vetmic.2018.04.026 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  30. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, WC Groutas, et al. . Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. (2016) 12: e1005531. 10.1371 / journal.ppat.1005531 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  31. Takano T, Endoh M, Fukatsu H, Sakurada H, Doki T, Hohdatsu T. The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection. Antiviral Res. (2017) 145: 96–102. 10.1016 / j.antiviral.2017.07.022 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  32. Takano T, Akiyama M, Doki T, Hohdatsu T. Antiviral activity of itraconazole against type I feline coronavirus infection. Vet Res. (2019) 50: 5. 10.1186 / s13567-019-0625-3 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  33. Doki T, Takano T, Kawagoe K, Kito A, Hohdatsu T. Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis. Res Vet Sci. (2016) 104: 17–23. 10.1016 / j.rvsc.2015.11.005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  34. Pedersen NC. An update on feline infectious peritonitis: virology and immunopathogenesis. Vet J. (2014) 201: 123–32. 10.1016 / j.tvjl.2014.04.017 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  35. Addie DD, Curran S, Bellini F, Crowe B, Sheehan E, Ukrainchuk L, et al. . Oral Mutian® X stopped faecal feline coronavirus shedding by naturally infected cats. Res Vet Sci. (2020) 130: 222–9. 10.1016 / j.rvsc.2020.02.012 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  36. Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol. (2019) 35: 57–62. 10.1016 / j.coviro.2019.04.002 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Myocarditis in naturally infected pets with the British variant of COVID-19

Luca Ferasin, DVM, Ph.D, Matthieu Fritz, Ph.D, Heidi Ferasin, DVM, Pierre Becquart, Ph.D, Vincent Legros, DVM, Ph.D and Eric M. Leroy
Original article: Myocarditis in naturally infected pets with the British variant of COVID-19; 3/18/2021; Translation 1.4.2021

Abstract

Pets may become infected with SARS-CoV-2, but based on the limited information available so far, it is not known whether the new UK variant B.1.1.7 can more easily infect certain animal species or increase the possibility of human-to-animal transmission. In this study, we report the first cases of infection of domestic cats and dogs by British variant B.1.1.7 SARS-CoV-2 diagnosed at a specialized veterinary hospital in the south-east of England. We further found that many owners and caregivers of these pets developed respiratory symptoms in Covid-19 3-6 weeks before their pets became ill, and also had a positive PCR test for Covid-19. Interestingly, all of these B.1.1.7 infected pets developed atypical clinical manifestations, including severe myocarditis-related cardiac abnormalities and severe deterioration of the patient's overall health, but without any primary respiratory symptoms. Our findings demonstrate for the first time the ability of pet animals to be infected with variant B.1.1.7 SARS-CoV-2 and raise questions about its pathogenicity in these animals. In addition, given the increased infectivity and transmissibility of variant B.1.1.7 for humans, these findings also highlight, more than ever, the risk that pets may potentially play a more important role in the dynamics of SARS-CoV-2 outbreaks than previously thought.

Introduction

The COVID-19 pandemic due to severe acute respiratory syndrome caused by type 2 coronavirus (SARS-CoV-2), characterized by a change in the amino acid spike protein (S) D614G (referred to as variant B. 1), has affected several million cases worldwide. This global situation has favored the occurrence of many genomic mutations, some of which have created variants with selective advantages. 1. At the end of autumn 2020, three notable variants emerged in several countries, which then spread rapidly around the world, including B.1.1.7 (also known as 20I / N501Y.V1), which was first identified in England. 2, B.1.351 (20J / N501Y.V2) first detected in South Africa and recently identified "Brazilian" variants of P.1 (20I / N501Y.V3). These three variants carry a constellation of genetic mutations, including those at the level of the protein S receptor binding domain (RDB), which is necessary for binding to the ACE-2 receptor of the host cell to facilitate virus entry.

It is estimated that variant B.1.1.7, also referred to as the dreaded variant (VOC) 202012/01 or 20I / 501Y.V1, appeared in September 2020 in Kent, a county in the south-east of England, and quickly surpassed other existing ones in England. variants due to increased portability and infectivity 2. Multiple evidence suggests that its increased portability is driven by the N501Y mutation and the Δ69 / 70 amino acid deletion in RDB 3. Subsequently, the incidence of B.1.1.7 increased during the national lockdown introduced by the UK Government from 5 November to 2 December 2020, despite severe restrictions, which led to an extraordinary increase in COVID-19 cases, which particularly affected the Greater London area. . As of February 7, 2021, VOC 202012/01 represented approximately 95% new SARS-CoV-2 infections in the United Kingdom and has currently been identified in at least 86 countries.

There have been several cases of SARS-CoV-2 infection in pets (especially cats and dogs) worldwide, and these animals are thought to have been infected by their owners or caregivers. Pet infections have mostly led to unnoticeable to mild digestive and respiratory symptoms such as cough, rhinitis, sneezing and conjunctivitis. 4-6. Interestingly, despite the uncontrolled increase in COVID-19 cases in the UK since November 2020, no SARS-CoV-2 infections have been reported in pets. More surprisingly, to the best of the authors' knowledge, no natural infection of any B.1.1.7 animal has ever been documented, either in England or anywhere else.

The results

We report a sudden increase in the number of domestic dogs and cats with myocarditis at The Ralph Veterinary Referral Center (RVRC) on the outskirts of London (UK) between December 2020 and February 2021, with an unexpected increase in incidence from 1.4% to 12.8% (8, 5% in cats and 4.3% in dogs). This sudden increase in cases appears to have followed the curve and timeline of the COVID-19 human pandemic in the UK as a result of option B.1.1.7, which began in mid-December 2020 and culminated in late January 2021 before returning to historical levels in mid-February. 2021

None of these myocarditis patients had a history of heart disease and their clinical picture was similar and characterized by acute onset of lethargy, anorexia, tachypnoea / dyspnoea (secondary to congestive heart failure) and in some cases syncopal events. Diagnostic examinations revealed the presence of elevated cardiac troponin-I (median 6.8; range 0.68 to 61.1 ng / ml [normal reference range 0.0-0.2 ng / ml]) accompanied by echocardiographic evidence of myocardial remodeling and / or signs of pleural effusion and / or pulmonary edema, often confirmed on chest radiographs, and / or severe ventricular arrhythmias on electrocardiography (see Additional Figure S1). All affected animals achieved remarkable improvement after cage rest, oxygen therapy, acute diuresis, and in some cases antiarrhythmic treatment with sotalol and fish oil before being discharged for oral treatment after several days of intensive care. Notably, most owners and caregivers of these pets with myocarditis developed respiratory symptoms in Covid-19 within 3-6 weeks before their pets became ill, and many of these owners had a positive PCR test for Covid-19. Due to this coincidence and the interesting simultaneous development of myocarditis in these pets and the outbreak of B1.1.7 COVID-19 in the UK, we decided to investigate SARS-CoV-2 infection in these animals. For this purpose, serum samples as well as oro / nasopharyngeal and rectal swabs were taken from seven animals (six cats and one dog) at the initial presentation at the RVRC between 22 January and 10 February 2021 (Table 1). During the same period, we took blood samples from four other pets (two cats and two dogs) during their recovery, 2-6 weeks after they developed symptoms of myocarditis. None of the 11 myocarditis animals developed any influenza-like symptoms and all improved clinically over several days of intensive care, although one cat (LL) had a relapse of her clinical symptoms characterized by severe lethargy and uncontrolled ventricular tachycardia one week after discharge. its owners to opt for euthanasia. All cats and dogs were neutered and aged from one to 12 years. After collection, all samples were stored at -20 ° C until transport on ice to the MIVEGEC laboratory in Montpellier, France for serological and virological examinations.

Kind ofTribeAgeGenderDaysGeneral symptomsT
° C
Cardiac abnormalitiesTroponin ng / mlCovid-19 + contactSNSARS-CoV-2 ddPCRSerology
?DSH9M2Lethargy
Anorexia
37.1CHF7.9✔️–––
?DSH9M2Lethargy
Anorexia
37.0CHF, VA0.68✔️–33 copies of RNA / µL–
?Manx12F2Lethargy35.2CHF, VA6.8❓–––
?Sphynx10F3Syncope37.9CHF, VA45.6❓–12 copies RNA / µL–
?Labrador9F4Lethargy
Anorexia
Hemorrhagic diarrhea
37.6VA43.5✔️–13 copies RNA / µL–
?DSH9M8Lethargy37.8CHF1.31❓––N protein
?Scottish Fold1M10Lethargy
Anorexia
37.3CHF12.1❓–––
?Mastiff8F14Syncope38.0CHF, VA2.5❓–ON THE–
?Siberian1F28Lethargy38.5CHF4.92✔️–ON THEN protein
RBD
S trimmer
?Dalmatian8M37Syncope38.2VA61.1✔️+ON THERBD
S trimmer
?Persian1M64Lethargy37.5CHF, VA0.83❓–ON THE–
Table 1: Characteristics of dogs and cats diagnosed with myocarditis at the Ralph Veterinary Clinic between 22 January and 10 February 2021
Days: Number of days between onset of symptoms and consultation with a veterinarian, DSH: Domestic shorthair, CHF: congestive heart failure, VA: Ventricular arrhythmia, NA: Not applicable

Oro / nasopharyngeal and rectal swabs were tested by droplet digital RT-PCR (ddPCR) targeting one region specific for the SARS-CoV-2 N gene and two Spike protein regions specific for the three current predominant SARS-CoV-2 variants, namely 20I / N501Y.V1, 20J / N501Y.V2 and 20I / N501Y.V3. One target region containing the N501Y mutation is common to three variants and the other target region containing the Δ69-70 deletion is specific to variant B.1.1.7. Sera were tested for SARS-CoV-2 specific IgG using three microsphere immunoassays (MIA) that detected IgG binding to N protein, S1-RBD protein or S trimeric protein, as well as a retrovirus-based assay to detect SARS-CoV-2. 2 neutralizing antibodies (see Materials and Methods).

All oro / nasopharyngeal swabs were found to be negative for SARS-CoV-2 ddPCRs. However, positive ddPCR signals were obtained for three areas from rectal swabs from three of the seven animals (two cats and one dog), indicating infection with British variant B.1.1.7. The RNA concentration ranged from 12 to 33 copies / μL of sample, indicating a low viral load (Table 1). In addition, samples from one animal taken during the acute phase of the disease, which showed a negative ddPCR result, as well as from two of the four animals taken during the recovery period, were found to contain SARS-CoV-2 antibodies. Thus, in total, six of our 11 animals tested were shown to be SARS-CoV-2 positive, either ddPCR or serologically. More interestingly, considering only five animals whose owners or caregivers were laboratory confirmed for Covid-19, four showed SARS-CoV-2 positive (Table 1).

Figure 1: The ECG trace recorded in one of the dogs shows signs of acute myocarditis showing persistent monomorphic ventricular tachycardia at 320 bpm (sample obtained from a 5-minute continuous 6-lead ECG recording, 50 mm / s, 10 mm / mV).

Discussion

As far as we know, this is the first report of an infection of cats and dogs by the British variant SARS-CoV-2 B.1.1.7. Given the increased infectivity and transmissibility of human B.1.1.7, the discovery of B.1.1.7 infected cats and dogs emphasizes more than ever the risk that pets may potentially play a significant role in the dynamics of SARS-CoV-2 outbreaks, as previously thought. Therefore, further studies are urgently needed to examine the likelihood of transmission of animal-animal as well as animal-human variant B.1.1.7 and to demonstrate whether the N501Y mutation and the Δ69-70 deletion cause the virus to be more infectious to these animals.

Another remarkable and unexpected finding of our study is the development of unusual clinical manifestations in cats and dogs infected with B.1.1.7, including severe cardiac abnormalities secondary to myocarditis and severe deterioration of the patient's overall health, but without any primary respiratory symptoms. With the exception of the only cat in Spain who experienced cardiorespiratory failure leading to severe respiratory distress 7, both natural and experimental SARS-CoV-2 infections have been reported in cats and dogs, either asymptomatic or with mild upper respiratory disease. Although B.1.1.7 infection in humans appears to be associated with higher COVID-19 mortality or clinical severity, the association between myocarditis and B.1.1.7 infection in pets should be recognized and addressed. 8 In this context, it is important to emphasize the fact that myocarditis associated with multisystem inflammatory syndrome is also a well-known complication of COVID-19 in humans (both adults and children), probably due to an exaggerated immune response of the host. 9,10.

Our findings demonstrate the ability of pet animals to become infected with SARS-CoV-2 B.1.1.7 and raise questions about its pathogenicity in these animals. Therefore, there is an urgent need to significantly accelerate and strengthen the investigation and surveillance of animal infections with highly transmissible variants such as British B.1.1.7, South African B1.351 and Brazilian P.1 as part of the global response to the ongoing multi-species pandemic of COVID-19.

Materials and methods

RNA extraction


Rectal and oro / nasopharyngeal swabs were resuspended by vortexing in 300 μL PBS. Total RNA was extracted from 200 μL of rectal swab supernatant and 200 μL of nasopharyngeal swab virus transport medium. Extraction was performed on an IndiMag 48 extraction system (Indical Bioscience) using magnetic bead technology with the IndiMag Pathogen kit according to the manufacturer's instructions. The elution volume was 100 μL.

One-step dRT-PCR


The RT-dPCR procedure was performed according to the manufacturer's instructions using a QIAcuity 8.5 plexus (Qiagen, Germany), a QIAcuity One-Step Viral RT-PCR kit (cat. No. 1123145, Qiagen, Germany) and a 24-well 26K nanoplate ( Cat. No. 250001, Qiagen, Germany). The ddRT-PCR technique showed higher sensitivity and specificity for the diagnosis of COVID-19 compared to RT-qPCR. 11

Briefly, the RT-dPCR reaction mixture was assembled as follows: 4x one-step viral RT-PCR Master Mix 10 μl, 100x multiplex reverse transcription mixture 0.4 μl, 20x primer and probe set 0149, 0130, 0150 (ref IAGE) 2 μl x3 (6 μL), RNase-free water 22.6 μl and RNA template 1 μl, in a final volume of 40 μl. Target 0130 target 2019-nCoV_N2 NC_045512v2 fluorophore HEX, amplicon length 67 bp. Target region 0149: deletion of mutations 69-70, lines B1.1 and B1.258, fluorophore HEX, amplicon length 100 bp. Target region 0150 S: mutation N501Y, line B1.1.7, fluorophore Cy5, amplicon length 133 bp. The sequences are confidential and are stored under number EP20306715.2. The mixture was prepared on a pre-plate and then transferred to a 24-well 26K nanoplate. It was then introduced into the QIAcuity 8, a fully automated system. The procedure included i) a priming and rolling step to generate and isolate the ventricular compartments, ii) an amplification step according to the following cyclic protocol: 50 ° C for 40 minutes for reverse transcription, 95 ° C for 2 minutes for enzyme activation, 95 ° C after for 5 s for denaturation and 60 ° C for 30 s for annealing / extension for 40 cycles and iii) the imaging step was performed by reading in the following channels FAM, HEX and CY5. The entire workflow time for these three steps was approximately 2 hours. Experiments were performed using a negative control (no template control, NTC) and a positive control (the patient sample was confirmed as positive by RT-PCR using our routine diagnostic testing). All reactions had at least 25,400 compartments. Data were analyzed using QIAcuity Suite Software V1.1.3 (Qiagen, Germany) and expressed as copies / μl.

Microsphere immunoassay


Serum samples from cats and dogs were tested by multiplex microscopic immunoassay (MIA). 10 μg of three recombinant SARS-CoV-2 antigens were used to capture specific serum antibodies: nucleoprotein (N), receptor binding domain (RBD) and trimeric spike (tri-S). Separate MagPlex microsphere kits (Luminex Corp) were appropriately coupled to viral antigens using an amine coupling kit (Bio-Rad Laboratories) according to the manufacturer's instructions, while the recombinant human protein-coupled microsphere kit (O6-methylguanine DNA methyltransferase) was used as a control in the assay. . The MIA procedure was performed as described in 12. Briefly, microsphere mixtures were sequentially incubated protected from light on an orbital shaker with serum samples (1: 400), biotinylated protein A and biotinylated protein G (4 μg / ml each) (Thermo Fisher Scientific) and Streptavidin-R-phycoerythrin (4 μg / ml) (Life technologies). Measurements were performed using a Magpix instrument (Luminex). Relative fluorescence intensities (RFI) were calculated for each sample by dividing the MFI signal measured for the antigen-coated sets of microspheres by the MFI signal obtained for the set of control microspheres to take into account the non-specific binding of the antibodies to the beads. Specific seropositivity limits for each antigen were set to three standard deviations above the mean RFI value of serum samples from 29 dogs and 30 cats collected before 2019. Based on the pre-pandemic population, the MIA specificity for N protein was set at 96.6%. for dogs and cats, 96.6% for RBD for cats and 100% for dogs and 100% for tri-S for cats and 96.6% for dogs.

Measurement of neutralizing activity


An MLV-based pseudo-particle carrying a SARS-CoV2 tip pseudotyped (SARS-CoV-2pp) was used to measure neutralizing activity in cat and dog sera. Each SARS-CoV2 positive sample detected by MIA was treated by a neutralization procedure as described in 13. The level of infectivity was expressed as % GFP positive cells and compared to SARS-CoV-2pp infected cells incubated without serum. Pre-pandemic sera from France were used as negative controls and anti-SARS-CoV-2 RBD antibody was used as a positive control.

Declaration of conflict of interest


None of the authors in this study has any conflict of interest (financial or personal).

Financing


The study was funded by the French National Research Agency (ANR-RA-COVID-19; Geographical and Temporal Serological Study of SARS-CoV-2 Pet Infection during the Second COVID-19 Wave in France, CoVet) and the IDEXLYON project from the Université de Lyon as part of the "Investissements d'Avenir Program" (ANR-16-IDEX-0005) and the Institut de Recherche pour le Développement (IRD).

Acknowledgement


We are grateful to the owners of the pets for giving us consent to take samples from their animals. We also thank Dr. Laurent Locquet and Dr. Altin Cala for contributing to the clinical management of these patients. We also thank Franz Durandet (IAGE - Environmental Engineering and Analysis, Grabels, France), Alix de Mont-Marin (Innovative Diagnostics, France) and Afif M. Abdel Nour (Qiagen, France) for their help in molecular biology. We also thank François Loïco Cosset, Solène Denolly, Bertrand Boson of CIRI - Center for International Research in Infectiology, Team EVIR, Univ Lyon, Claude Bernard Lyon 1 University, Inserm, U111, UMR5308, ENS Lyon, for the development of seroneutralization technology. In conclusion, we thank Dr. Thierry Buronfosse for the kind gift of pre-pandemic sera.

References

  1. Rambaut, A., et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature microbiology 5, 1403–1407 (2020).Google Scholar
  2. (PHE), PHE Investigation of novel SARS-CoV-2 variant: Variant of concern 202012/01: Technical briefing 6. London: PHE. 13 Feb 2021. Available from: www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201 (2021).Google Scholar
  3. Leung, K., Shum, MH, Leung, GM, Lam, TT & Wu, JT Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro surveillance: bulletin Europeen sur transmissible males = European communicable disease bulletin 26 (2021).Google Scholar
  4. Barrs, V., et al. SARS-CoV-2 in Quarantined Domestic Cats from COVID-19 Households or Close Contacts, Hong Kong, China. Emerging Infectious Disease journal 26, 3071 (2020).Google Scholar
  5. Hosie, MJ, et al. Respiratory disease in cats associated with human-to-cat transmission of SARS-CoV-2 in the UK. bioRxiv, 2020.2009.2023.309948 (2020).Google Scholar
  6. Sit, THC, et al. Infection of dogs with SARS-CoV-2. Nature 586, 776–778 (2020).Google Scholar
  7. Segalés, J., et al. Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain. Proceedings of the National Academy of Sciences 117, 24790–24793 (2020).Abstract / FREE Full TextGoogle Scholar
  8. Challen, R., et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 372, n579 (2021).Abstract / FREE Full TextGoogle Scholar
  9. Morris, SB, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 69, 1450–1456 (2020).CrossRefPubMedGoogle Scholar
  10. Valverde, I., et al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Circulation 143, 21–32 (2021).Google Scholar
  11. Falzone, L., et al. Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection. Int J Mol Med 46, 957–964 (2020).CrossRefGoogle Scholar
  12. Fritz, M., et al. High prevalence of SARS-CoV-2 antibodies in pets from COVID-19 + households. One Health 11, 100192 (2021).Google Scholar
  13. Legros, V., et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cellular & Molecular Immunology 18, 318–327 (2021).Google Scholar

A retrospective study of clinical and laboratory features and treatment on cats highly suspected of feline infectious peritonitis in Wuhan, China

4.3.2021; Translation 16.4.2021
Yiya Yin, Ting Li, Chaohao Wang, Xiaoya Liu, Hehao Ouyang, Wanfeng Ji, Jiahao Liu, Xueyu Liao, Junyi Li, and Changmin Hu

Original article: A retrospective study of clinical and laboratory features and treatment on cats highly suspected of feline infectious peritonitis in Wuhan, China

Abstract

Feline infectious peritonitis (FIP) is a systemic, potentially fatal viral disease. The aim of this study was to investigate the clinical and laboratory characteristics and treatment of cats with highly suspected FIP in Wuhan, China. The clinical records of 127 cats with highly suspicious FIP were reviewed for history, clinical signs, physical findings, and diagnostic test results. Gender, castration status, breed, age and month of onset of the disease were compared with the characteristics of the clinical population. Age and castration status were significantly correlated with suspected FIP. Gender, breed and month of onset of symptoms were not related to FIP. Many more cases of suspected FIP have been reported in young cats or intact males. The effusion was observed in 85.8% cats suspected of having FIP. Elevations in serum amyloid A (SAA) and lymphopenia were common abnormalities in FIP cases. Furthermore, 91.7% cats with highly suspected FIP had an albumin / globulin (A / G) ratio <0.6, while 85.3% had an A / G ratio <0.5. Mortality for cats suspected of FIP was 67% and six cases were confirmed by FIP-specific immunohistochemistry. Of the 30 cats treated with GS-441524 and / or GC376, 29 were clinically cured. The study highlights the diversity of clinical manifestations in the diagnosis of this potentially fatal disease. The A / G ratio and SAA had a higher diagnostic value. GS-441524 and GC376 have been shown to be effective in treating cats suspected of having FIP.

Keywords: Zoology, Diagnosis of infectious diseases

Introduction

Infectious feline peritonitis (FIP) is a worldwide disease of domestic and feral cats. The pathogen of FIP is feline infectious peritonitis virus (FIPV), which was caused by a mutation in feline coronavirus (FCoV) 1,2. Although extensive FIP research has been conducted, FIP remains one of the most widespread and deadly infectious diseases in cats.

In addition to non-specific clinical symptoms such as malaise, anorexia, fluctuating fever, and weight loss, the clinical picture of FIP is complex and variable. Different clinical signs may be the result of variations in the virus and the nature of the individual host's immune response. FIP can be divided into three types - effusive, non-effusive and mixed - depending on the different clinical features that occur, these types may change over time for each individual cat. Effusive (wet) FIP manifests itself mainly as ascites and / or pleural effusion, while non-effusive (dry) FIP manifests itself mainly by the formation of granulomas in the central nervous system, eyes and abdominal organs and does not produce effusion in the body cavity.3. If the symptoms of effusive and non-effusive form appear simultaneously, it is a mixed FIP4. To our knowledge, there are few studies on the clinical and laboratory properties of FIP in China.

Diagnosing FIP before death is a controversial and complicated issue. It is more difficult to diagnose FIP in vivo in non-exuding cats because the clinical signs and laboratory characteristics are relatively unclear. Immunofluorescence staining of FCoV antigen in macrophages is highly specific, but is difficult to detect due to the low number of macrophages in the effusion. Immunohistochemistry (IHC) is currently the gold standard for FIP diagnostics to identify FCoV antigens in affected tissues. However, this invasive method has low operability and requires professional detection equipment and personnel. At the same time, a negative IHC result does not rule out the diagnosis of FIP, which poses another challenge for the diagnosis of this disease.5. FIP has an extremely high mortality rate and until recently was considered a fatal disease. In recent years, a 3C protease inhibitor (GC376) and a nucleoside analogue (GS-441524) have been shown to have some therapeutic effect on FIP.6-9. The purpose of this study is to determine the epidemiological properties and associated risk factors of FIP, to summarize common clinical signs and laboratory characteristics, and to evaluate the therapeutic effects of GS-441524 and GC376.

Materials and methods

Case selection

This study retrospectively evaluated medical records in a database of 12 veterinary hospitals in Wuchan, China, from January 1, 2019 to January 1, 2020. Due to the limitations of diagnostic facilities in veterinary hospitals and the reluctance of cat owners to consent to invasive diagnostic procedures such as biopsy, most cases were not confirmed by the IHC. Therefore, based on previously published literature in this area, the following inclusion criteria have been established for the diagnosis of suspected FIP cases.5-15. Highly suspected cases of FIP were defined as those that met at least four of the following characteristics: 1) Typical clinical signs of FIP effusion (pleural effusion and / or ascites) or typical clinical signs of non-fusive FIP (ocular and neurological symptoms); 2) Decreased albumin / globulin ratio (A / G <0.6); 3) Rival's test showing positive results in effusion; 4) Positive detection of FCoV RNA in reverse transcription polymerase chain reaction (RT-PCR) effusion; 5) Tissue samples taken at necropsy that show typical histological features of FIP, namely systemic vasculitis and pyogranulomatous lesions.

Of the 20,984 cats registered in 12 veterinary hospitals, 127 cases with a high suspicion of FIP were included according to the above criteria. Through the collection of background information, history, clinical signs, haematological and biochemical analyzes, diagnostic imaging, RT-PCR, Rivalt's test, exploratory laparotomy and histopathology, cases were comprehensively diagnosed and analyzed and detailed information and test results were recorded (see Supplemental Table S1 for FIP case record sheet). All information was collected with the consent and cooperation of veterinarians and cat owners. The protocol was approved by the Animal Management and Ethics Committee of the Center for Laboratory Animals at Huazhong Agricultural University (approval number: HZAUCA-2018-005).

Statistical analysis

Statistical analysis was performed using commercial software (SPSS version 21.0 [IBM]). Descriptive statistics were used for all variables evaluated. Categorical data were analyzed using Pearson's chi-square test (χ2). Fisher's exact two-tailed results were used in 2 × 2 contingency tables with expected cell values <5. The sex, castration, breed, age, and onset of symptoms of suspected FIP were compared to a feline clinical population (20,984 cats) presented from January 2019 to January 2020 from 12 veterinary hospitals to determine if these risk factors were associated with FIP.

The history, clinical signs, and laboratory results of FIP suspicions were retrospectively analyzed to summarize common clinical signs and laboratory abnormalities of the disease. Samples were randomly selected from cats undergoing a laparotomy and sent to LABOKLIN GMBH & CO. KG. KG (Bad Kissingen, Germany) to the IHC to verify that the inclusion criteria for FIP cases are correct and justified. In addition, the therapeutic effect of GS-441524 and GC376 was evaluated.

Ethical approval

All relevant international, national and institutional guidelines for the care and use of animals have been complied with. All procedures performed in animal studies were in accordance with the ethical standards of the institution in which the studies were performed.

The results

Risk factors

No significant correlation was found between FIP and gender (p = 0.083). However, FIP significantly correlated with castration status (p <0.001) and intact males were more susceptible to the disease. Regarding the breed, whether classified as crossbred or purebred (p = 0.069) or specific to each breed (p = 0.246), no correlation was found with the FIP. There was a significant correlation between age and FIP (p <0.001) and young cats were more susceptible. The age of cases of suspected FIP ranged from 1 month to 8 years and 2 months, with a mean age of 13.1 months and a median age of 8 months. In these cases, 40.2% was less than 6 months old, 67% was less than 1 year old, and 90.6% was less than 2 years old; in addition, the prevalence in older cats was significantly lower than the prevalence in young cats (Table 1). The correlation of the month of onset of the disease was studied for the first time and the number of cats suspected of having FIP and the clinic population were counted for each month. The results showed that the highest prevalence was 1% in May. The prevalence in January (0.95%), February (0.87%), September (0.66%) and November (0.77%) was higher than the overall prevalence and the lowest prevalence was 0.35% in July. However, in the statistical analysis, there was no correlation between FIP and month (p = 0.135; Table 1).

Table 1

Risk factors for cats with a high suspicion of FIP compared to the clinical population.

Risk factors Suspected FIP (n= 127) Clinical population (n= 20984) χ2 p Value OR 95% CI
Gender n= 127 (%) n= 17,494 (%) 3.009 0.083    
Male 78 (61.4) 9397 (53.7)     1.372 0.958–1.963
Female 49 (38.6) 8097 (46.3)     0.729 0.509-1.043
Castration status n= 127 (%) n= 16041 (%) 45.684 <0.001 ***    
Uncastrated male 69 (54.3) 4887 (30.5)     Ref  
Castrated male 9 (7.1) 3791 (23.6)     0.168 0.084-0.337
Uncastrated female 39 (30.7) 4472 (27.9)     0.618 0.416-0.917
Castrated female 10 (7.9) 2891 (18.0)     0.245 0.126-0.476
Tribe n= 127 (%) n= 16469 (%) 3.307 0.069    
Crossed 36 (28.3) 5953 (36.1)     0.699 0.474–1.029
Purebred 91 (71.7) 10,516 (63.9)     1.431 0.972–2.108
Breed (specific) n= 127 (%) n= 16469 (%) 16.752 0.053    
Crossed 36 (28.3) 5953 (36.1)     Ref  
British Shorthair 60 (47.2) 6558 (39.8)     1.513 0.999-2.290
American Shorthair 8 (6.3) 1275 (7.7)     1.038 0.481–2.237
Ragdoll 9 (7.1) 877 (5.3)     1.697 0.815–3.535
Siamese 6 (4.7) 430 (2.6)     2.307 0.967–5.506
Exotic cat 3 (2.4) 1019 (6.2)     0.487 0.150-1.584
Chinchilla (Persian) 2 (1.6) 258 (1.6)     1.282 0.307-5353
Scottish Fold 1 (0.8) 44 (0.3)     3.758 0.504-28281
American curl 1 (0.8) 28 (0.2)     5.906 0.782–44.581
Bengali 1 (0.8) 27 (0.2)     6.124 0.810–46.291
Age groups n= 127 (%) n= 19772 (%) 220.276 <0.001 ***    
≤ 6 M 51 (40.2) 1530 (7.7)     Ref  
6 M <A ≤ 1Y 34 (26.8) 3254 (16.5)     0.313 0.202-0.486
1Y <A ≤ 2Y 30 (23.6) 4660 (23.6)     0.193 0.123-0304
2Y <A ≤ 4Y 8 (6.3) 4027 (20.4)     0.060 0.028-0.126
4Y <A ≤ 7Y 3 (2.4) 3507 (17.7)     0.026 0.008-0.082
A> 7Y 1 (0.8) 2794 (14.1)     0.011 0.001-0.078
Starting months n= 127 (%) n= 20984 (%) 16.166 0.135    
January 16 (12.6) 1685 (8.0)     Ref  
February 13 (10.2) 1500 (7.1)     0.913 0.438–1.904
March 7 (5.5) 1768 (8.4)     0.417 0.171-1,016
April 7 (5.5) 1656 (7.9)     0.445 0.183-1.085
May 17 (13.4) 1689 (8.1)     1.054 0.531–2.094
June 10 (7.9) 2109 (10.1)     0.499 0.226–1.103
July 7 (5.5) 2022 (9.6)     0.365 0.150-0.888
August 9 (7.1) 1773 (8.4)     0.535 0.236–1.213
September 12 (9.4) 1812 (8.6)     0.697 0.329–1.479
October 8 (6.3) 1734 (8.3)     0.486 0.207–1.138
November 13 (10.2) 1698 (8.1)     0.806 0.387–1.681
December 8 (6.3) 1529 (7.3)     0.551 0.235–1.291

Data expressed as n (%); χ2= Chi-square; OR = Odds ratio; CI = Confidence Interval; Ref = Reference category; A = Age; Y = Years; ***: p<0.001, expresses a statistically significant difference.

Pre-diagnosis stress events were documented in 60/127 cats. Because some cats had more stressors, a total of 77 stressors were recorded. Of these events, environmental change was the most common factor leading to stress (40.3%), followed by new domestic pets that coexisted with other diseases, intimidation, and dietary changes (Fig. 1). In addition, information was collected on the density of domestic cats, of which 43 (51.8%) were single-cat households and 40 (48.2%) were single-cat households.

Figure 1
Frequency of documented stress situation of cats with high suspicion of FIP.

Clinical signs

Of the 127 cats with highly suspicious FIP, 12 (9.4%) developed dry FIP and 109 (85.8%) developed effusive FIP, of which 92 exhibited ascites (84.4%), 11 had pleural effusion (10.1%). and 6 with ascites and pleural effusion (5.5%). In addition, 6 cats (4.7%) had mixed FIP. Some first developed dry FIP, followed by ascites and the development of effusive FIP. Some cats initially showed effusive FIP and developed neurological symptoms several days before death.

The clinical signs of cats with a high suspicion of FIP are listed in Table 2. The most common non-specific signs were weight loss (93.8%), malaise (86.2%) and anorexia (86%). In more than half of the cases, jaundice and 59.4% and 52.9% fever, respectively, were present. Of the 85 cats with highly suspected FIP for whom the temperature was documented on physical examination, 52.9% had a temperature above 39.5 ℃, 36.5% had a temperature above 40 ℃ and 10.6% had a temperature above 40.5 ℃ (see Additional Figure S1.). As a result, the 41.3% cats had a palpable mass on abdominal palpation, which could be either an enlargement of the mesenteric lymph nodes or an increase in the intestinal wall. Diarrhea was less common and occurred in only 17.6%, while dyspnoea occurred in 35.2% and was most common in cats with pleural effusion. In addition, ocular and neurological symptoms generally occurred only in dry or mixed forms of FIP.

Table 2

Clinical signs of cats with high suspicion of FIP.

Clinical signs Examined animals (n) Number of cats with clinical signs (n) Percentage of cats with clinical signs (%)
Weight loss 64 60 93.8
Illness 94 81 86.2
Anorexia 100 86 86
Jaundice 64 38 59.4
Fever 85 45 52.9
Abdominal mass 63 26 41.3
Dyspnoea 71 25 35.2
Diarrhea 85 15 17.6
Eye symptoms 103 9 8.7
Neurological symptoms 103 9 8.7
FIP tips
Dry 127 12 9.4
Ascites 127 92
Efusive pleural 127 11 85.8
Both 127 6
Mixed 127 6 4.7

Ocular symptoms included uveitis, corneal edema, edema, anisocoria, and retinal detachment. Neurological symptoms included ataxia, hind limb paralysis, nystagmus, twitching, and salivation. Number of data specified as n.

Hematology and serum biochemistry

As shown in Table 3, hematocrit (HCT) decreased in 40.2% cats, but only in 15.9% cats there was a decrease in red blood cell (RBC) counts. Half of the cats developed lymphocytopenia, 33.9% had an increase in white blood cell (WBC) count, and 34.3% had an increase in neutrophil count (NEU).

Table 3

Hematology and serum biochemistry of cats with high suspicion of FIP.

Measurement Units Reference interval Examined animals Range Average Median Increased Reduced Normal
Red blood cells × 1012/ L 5–10 107 3.22–12.5 6.78 6.81 7 (6.5) 17 (15.9) 83 (77.6)
Haematocrit % 24–45 82 13.8–46.6 26.68 26 2 (2.4) 33 (40.2) 47 (57.3)
White blood cells × 109/ L 5–18.9 109 0–71.9 17.23 15.6 37 (33.9) 8 (7.3) 64 (58.7)
Lymphocytes × 109/ L 1.5–7.8 106 0–27.8 3.42 1.45 11 (10.4) 53 (50.0) 42 (39.6)
Neutrophils × 109/ L 2.5–12.5 35 0-30.83 9.7 7.93 12 (34.3) 8 (22.9) 15 (42.9)
Total protein g / L 57–89 109 47–120 75.77 76 16 (14.7) 11 (10.1) 82 (75.2)
Albumin g / L 22–40 109 10–33 20.96 21 0 64 (58.7) 45 (41.3)
Globulin g / L 28–51 109 30-96 55.03 53 63 (57.8) 0 46 (42.2)
Albumin / Globulin / / 109 0.137-0.767 0.399 0.385 / / /
Total bilirubin /mol / L 0-15 76 0.8–147.1 25.2 15 37 (48.7) 0 39 (51.3)
Alanine aminotransferase U / L 12–130 101 10–488 49.31 35 5 (5.0) 13 (12.9) 83 (82.2)
Alkaline phosphatase U / L 14–111 74 0–155 35.53 27.5 3 (4.1) 19 (25.7) 52 (70.3)
Creatinine /mol / L 71–212 94 7.3–302 79.04 71 1 (1.1) 45 (47.9) 48 (51.1)
Urea mmol / L 5.7–12.9 89 2.2–44.27 6.05 5.1 2 (2.2) 54 (60.7) 33 (37.1)
Amylase U / L 500-1500 39 26–3178 1356.01 1187 13 (33.3) 2 (5.1) 24 (61.5)
Lipase U / L 100-1400 11 81–1163 460.91 470 0 2 (18.2) 9 (81.8)
Feline serum amyloid mg / L 0–8 44 16.9–253 121.82 118.35 44 (100.0) 0 0

Data expressed as n (%).

In serum biochemistry, total protein (TP) levels were mostly normal (75.2%); several (14,7%) cats had elevated levels and very little had decreased levels. More than half of the cats with highly suspected FIP showed hypoalbuminemia (58.7%). Although albumin (ALB) levels in the remaining cats were normal, they were also close to the lower end of the reference range. Hyperglobulinemia was also common in cats with a high suspicion of FIP (57.8%) and the rest of the cats had normal globulin levels (GLOB). The A / G ratio ranged from 0.137 to 0.767, with a mean of 0.399 and a median of 0.385. Among the results, 91.7% was less than 0.6, 85.3% was less than 0.5, and 54.1% was less than 0.4 (see Additional Figure S2). An increase in total bilirubin (TBIL) was observed in almost half of the cats with highly suspected FIP (48.7%) and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were mostly normal. Creatinine (CRE) decreased in 47.9% cats, while urea decreased in 60.7% cats and rarely increased. Amylase (AMYL) and lipase (LIPA) were mostly negative and positive in only a small number of cats. In addition, feline serum amyloid A (SAA) increased in all cats (Table 3).

Imaging and molecular biology

Of the 127 cats, 90 were examined by ultrasound, which showed varying degrees of ascites, and several cats showed loss of corticomedullar resolution in the kidneys. Radiography was performed on 21 cats that showed pleural effusion and / or ascites (Fig. 2). Of the 109 cats with exudate, 98 exuded the exudate. We then detected FCoV RNA in 98 effusions by RT-PCR, with 83 cats (84.7%) showing FCoV positivity. The FCoV mutation was detected in 34 FCoV-positive effusions with 12 successfully sequenced and obtained partial sequences of the S gene, all of which had M1058L or S1060A mutations. In addition, Rivalta's tests were performed in 85 cases with a positivity rate of 100%; FCoV antibody tests were performed in 12 cases and all were positive. Microscopic examination of swabs from 25 cat effusions showed many pink protein granules and an increase in inflammatory cells.

Figure 2
Results of a clinical examination of a 4-month-old intact female British Shorthair cat with wet FIP. (a) Ultrasound showed a large amount of ascites in which the intestine was floating; (b) radiography revealed a large amount of effusion in the abdominal cavity; (c) the surface of the kidney was studded with militia white nodules; (d) ascites and enlarged mesenteric lymph nodes were observed. (e) Moderate pyogranulomatous interstitial nephritis (hematoxylin and eosin, × 400). The interstitium of the cortex showed focal marked infiltration by macrophages, lymphocytes, neutrophils and some plasma cells; (f) renal macrophages were stained strongly positive for FCoV antigen by immunohistochemistry, × 400.

Histopathology and immunohistochemistry

13 cats underwent an exploratory laparotomy and histopathological diagnosis was performed on 9 cats (for details on 13 cats, see Additional Table S2). After exploratory laparotomy, the samples were subjected to histopathological examination and we found typical pathological changes of FIP, namely systemic vasculitis and pyogranulomatous lesions (Fig. 2). Tissue samples from six cats were randomly sent to LABOKLIN GMBH & CO. KG. KG for IHC. This testing revealed that tissue macrophages showed positive staining for FCoV antigen, confirming the diagnosis of FIP (see Additional Figure S3-S8).

Treatment and results

The results of 88 cats were recorded. Of these, 59 eventually died with a mortality rate of 67%. Thirty-two cats were directly euthanized. Twenty-six cats underwent no treatment or were treated only for symptoms and eventually died naturally. Only one dry FIP was treated with GS-441524 for 4 weeks. After the disease subsided, the owner decided to stop the treatment and the cat eventually relapsed and was killed. In addition, 29 cats (25 wet, 3 dry and 1 mixed) were treated with GS-441524 (2-4 mg / kg, once daily for at least 4 weeks) or GC-376 (6-8 mg / kg) once daily after for at least 4 weeks) with a success rate of 33%. The most visible signs were rapid loss of ascites and / or pleural effusion (within 1 week), recovery of psyche and appetite, and weight gain. The cat with a wet FIP, which was diagnosed on January 1, 2019 and survived for more than a year, survived the longest.

Discussion

In the past, FIP was considered a deadly disease by scientists. In addition, it is difficult to apply the IHC gold standard in FIP diagnostics in China. With the development of research, breakthroughs have gradually been made in the treatment of FIP, such as studies on GS-441524 and GC376 6-9.16. However, the side effects of the two medicines are not clear and cannot be used immediately for clinical treatment. Therefore, the establishment of a more accurate diagnostic system is essential for the FIP in China. This paper examined 127 cases of FIP in Wuhan, China, and studied the diagnostic methods of several hospitals. He focused on clinicians' clinical practices in diagnosing the disease and improving the FIP diagnostic system.

This study collected data from 127 cases with highly suspected FIP, where 13 cats underwent exploratory laparotomy, 9 samples from cats with high suspicion of FIP underwent histopathology, and 6 samples underwent IHC, all of which were finally confirmed as FIP. Therefore, the inclusion criteria for the cases in this study were justified. Many studies and studies have been conducted on FIP based on the analysis of highly suspicious cases, which could not be diagnosed by gold standard (IHC) methods, but still provided a high reference value for the diagnosis and treatment of FIP.17–22. In addition, the implementation of invasive diagnostic methods has been difficult in clinical practice. Even owners of cats who chose euthanasia were not willing to accept the autopsy after death. Thus, if the IHC is not available, a more accurate diagnosis of a case of suspected FIP is a problem that veterinarians are currently paying close attention to.

In this study, the prevalence of cats with highly suspected FIP was 0.61%. Riemer's research in Germany showed that the prevalence of FIP was 1.42% 14. Previous studies have also shown that the prevalence of FIP in households with one cat or with two cats was 0.02%, while the prevalence in shelters was 5-10%. 23,24. No correlation was found between gender and FIP. However, some studies have suggested that males are more susceptible to FIP25. The prevalence of intact males was significantly higher than that of other groups and the prevalence of neutered cats was lower, consistent with Rohrbach's findings.26. This may be because sex hormones, especially androgens, have a negative effect on the immune system and increase the risk of viruses spreading and mutating.27. As mentioned above, this study showed that FIP is significantly associated with age, so young cats are more susceptible, probably because the immature immune system and various stressors have often led to a high viral load in young cats. It is possible that the increased rate of uncastrated cats may have been partly due to the young age of the infected cats, which means that the disease occurred before the age of castration. Purebred cats were previously considered more susceptible to FIP. However, a growing number of studies, including this study, showed that the proportion of purebred cats compared to the clinic population did not deviate from the average.14. This study also examined the regularity of the FIP outbreak month, which was not considered in other FIP-related epidemiological surveys, and ultimately found no significant difference in FIP prevalence by month. This study reported stressors in 60 cats, the most common of which was environmental change. There is no doubt that stress can inhibit immune function and increase the susceptibility of viruses to mutations and multiplication.10. Housing density was also considered to be one of the main risk factors for FIP, and overcrowding could lead to virus mutations and disease development.14. In any case, several cats with a high suspicion of FIP in this study came from single-cat households. This may be because these cats were exposed to FCoV when they lived in a multi-cat household as a child and then moved to a single cat household before developing FIP.

Most of the FIP cases presented were effusive (up to 85.8%), most of which were ascites. FIP can affect systemic organs, most commonly abdominal organs, including the intestine, mesenteric lymph nodes, liver, kidney, and spleen. Neurological and ocular symptoms were typical features of dry FIP. A retrospective study of 286 cats with neurological disease showed that FIP was one of the main causes of neurological diseases in cats28. In this study, 52.9% infected cats had a temperature greater than 39.5 ° C and 36.5% had a temperature greater than 40 ° C. Another study showed that the proportion of cats with fever was higher, where 82% cats had a temperature higher than 39.5 ℃ and 39% had a temperature higher than 40 ℃; Fever has also been found to be more common in effusive FIP14. Cases of pericardial effusion, swelling of the scrotum or skin papules, which are not common but could not be ignored during routine examination, have not been reported. The clinical signs of FIP always change over time (for example, gradual effusion and changes in fundus), so repeated clinical examination was very important to avoid delays in diagnosis and treatment.

Changes in serum hematology and biochemistry could only increase or decrease the suspicion of FIP, but could not be used as a definitive diagnostic method. In this study, there were no apparent signs of haematological changes in the diagnosis of FIP cases, with a decrease in HCT in 40,2% cats and LYM in 50% cats. However, many studies have shown that lymphocytopenia is the most common haematological abnormality of FIP caused by natural or experimental infection.29,30caused by virus-induced T-cell apoptosis31. In this study, we hypothesize that protein testing plays an important role in the diagnosis of FIP cases. ALB decreased in 58.7% cats and GLOB increased in 57.8% cats, so when both occurred simultaneously, TP often remained within the normal range. Therefore, only 14.7% cats showed an increase in TP. Both hyperglobulinemia and hypoalbuminemia may have increased the suspicion of FIP, but the most important serum biochemical abnormality was the A / G ratio. The A / G ratio decreased in almost all cases of FIP. Different studies have yielded different results regarding the effective critical value of the A / G ratio32. According to the A / G ratios in this study (91.7% <0.6, 85.3% <0.5 and 54.1% <0.4), a ratio of 0.5 can be considered a critical value. When the A / G ratio was> 0.8, the probability of FIP was very small; when the ratio was 0.533. Therefore, we hypothesize that an increase in SAA may help diagnose FIP.

Compared to serum detection, detection and analysis of body effusion has a better predictive value in cats.32. The positivity rate of the Rivalt test in this study was 100%. The study indicated that the sensitivity of the Rivalt test was 91.3%, the specificity was 65.5%, the positive predictive value was 58.4%, and the negative predictive value was 93.4%. 34. Rival's test is a cheap and fast detection method that does not require expensive instruments and is easy to handle. In view of good sensitivity and negative predictive value, the Rivalt test should be included in the diagnosis of each fed cat.15. The positive rate of FCoV RNA detected by RT-PCR was 84.7%. However, all coronaviruses, including FCoV, often mutate and recombine, so RT-PCR designed for specific sequences could not amplify all FCoV35 and positive results only represented the presence of FCoV, but not exact FIPV.

In this study, a total of 24 cats were treated with GS-441524, of which 23 were cured. Only one cat relapsed after 4 weeks of treatment and was eventually sacrificed. GS-441524 treatment for more than 8 weeks has been shown to be highly effective. Treatment with GC376 alone or in combination with GS-441524 was also effective. In fact, most of the terminal deaths were due to absence of treatment, purely symptomatic treatment, or euthanasia. In addition, Pruijssers and Denison have suggested that the combination of strong broad-spectrum anti-coronavirus drugs may increase efficacy and reduce the incidence of drug resistance.36.

In conclusion, it can be stated that the FIP did not correlate with gender, breed or month, but significantly correlated with age and castration status. FIP was significantly more common in young cats or intact males. Wet FIP was the most common clinical form. Decreased A / G ratio, increased SAA and lymphopenia were common laboratory abnormalities. GS-441524 and GC376 have been shown to be effective in treating cats with suspected FIP.

Additional information

Complementary pictures. (5.0 million Docx)

Thanks

The authors would like to thank the veterinarians and owners of the cats, without whose help this study would not have been possible. The study was funded by the National Key Research and Development Plan (No. 2020YFC08845600) and Huazhong Agricultural University. The study was performed in accordance with ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines (https://arriveguidelines.org).

Author's contributions

Study concept and design: CH and Y.Yin. Data collection: YY, HO, WJ, JL, XL and JL Data analysis: YY, TL, CW and XL Manuscript: YY and CH All authors reviewed the manuscript.

Data availability

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Conflict of interests

The authors are not aware of any conflict of interest.

Footnotes

Publisher Note

Springer Nature remains neutral in terms of jurisdictional claims in published maps and institutional links.

References

  1. Bank-Wolf BR, et al. Mutations of 3c and spike protein genes correlate with the occurrence of feline infectious peritonitis. Vet. Microbiol. 2014;173: 177–188. doi: 10.1016 / j.vetmic.2014.07.020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  2. Lewis CS, et al. Genotyping coronaviruses associated with feline infectious peritonitis. J. Gen. Virol. 2015;96: 1358. doi: 10.1099 / vir.0.000084. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  3. Norsworthy, GD, Grace, SF, Crystal, MA & Tilley, LP The feline patient (4thed), 181–183 (John Wiley & Sons, New York, 2011).
  4. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963–2008. J. Feline Med. Surg. 2009;11: 225–258. doi: 10.1016 / j.jfms.2008.09.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  5. Sykes JE. Canine and Feline Infectious Diseases, 195–208. WB Saunders; 2014. [Google Scholar]
  6. Kim Y, et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 2016;12: 1–18. [PMC free article] [PubMed] [Google Scholar]
  7. Murphy BG, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet. Microbiol. 2018;219: 226–233. doi: 10.1016 / j.vetmic.2018.04.026. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  8. Pedersen NC, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J. Feline Med. Surg. 2018;20: 378–392. doi: 10.1177 / 1098612X17729626. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  9. Pedersen NC, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J. Feline Med. Surg. 2019;21: 271–281. doi: 10.1177 / 1098612X19825701. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  10. Addie, DD et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. J. Feline Med. Surg.11, 594–604 (2009). [PMC free article] [PubMed]
  11. Greene CE. Infectious diseases of the dog and cat, 92–108. WB Saunders; 2012. [Google Scholar]
  12. Kipar A, Meli ML. Feline infectious peritonitis: still an enigma? Vet. Pathol. 2014;51: 505–526. doi: 10.1177 / 0300985814522077. [PubMed] [CrossRef] [Google Scholar]
  13. Pedersen NC. An update on feline infectious peritonitis: diagnostics and therapeutics. Vet. J. 2014;201: 133–141. doi: 10.1016 / j.tvjl.2014.04.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  14. Riemer F, Kuehner KA, Ritz S, Sauter-Louis C, Hartmann K. Clinical and laboratory features of cats with feline infectious peritonitis – a retrospective study of 231 confirmed cases (2000–2010) J. Feline Med. Surg. 2016;18: 348–356. doi: 10.1177 / 1098612X15586209. [PubMed] [CrossRef] [Google Scholar]
  15. Felten S, Hartmann K. Diagnosis of feline infectious peritonitis: a review of the current literature. Viruses. 2019;11: 1068. doi: 10.3390 / v11111068. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  16. Dickinson PJ, Bannasch M, Thomasy SM, et al. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. J. Vet. Intern. Med. 2020;34: 1587–1593. doi: 10.1111 / jvim.15780. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  17. Soma T, Ishii H. Detection of feline coronavirus antibody, feline immunodeficiency virus antibody, and feline leukemia virus antigen in ascites from cats with effusive feline infectious peritonitis. J. Vet. Med. Sci. 2004;66: 89–90. doi: 10.1292 / jvms.66.89. [PubMed] [CrossRef] [Google Scholar]
  18. Simons FA, et al. A mRNA PCR for the diagnosis of feline infectious peritonitis. J. Virol. Methods. 2005;124: 111–116. doi: 10.1016 / j.jviromet.2004.11.012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  19. Can-Şahna K, Ataseven VS, Pınar D, Oğuzoğlu TÇ. The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. J. Feline Med. Surg. 2007;9: 369–372. doi: 10.1016 / j.jfms.2007.03.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  20. Sharif S, et al. Evaluation of feline coronavirus viraemia in clinically healthy and ill cats with feline infectious peritonitis. J. Anim. Vet. Adv. 2011;10: 18–22. doi: 10.3923 / javaa.2011.18.22. [CrossRef] [Google Scholar]
  21. In C, et al. Circulation and genetic diversity of Feline coronavirus type I and II from clinically healthy and FIP-suspected cats in China. Transbound. Emerg. Dis. 2019;66: 763–775. doi: 10.1111 / tbed.13081. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  22. Lorusso E, et al. Discrepancies between feline coronavirus antibody and nucleic acid detection in effusions of cats with suspected feline infectious peritonitis. Res. Vet. Sci. 2019;125: 421–424. doi: 10.1016 / j.rvsc.2017.10.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  23. Pedersen NC. Serologic studies of naturally occurring feline infectious peritonitis. Am. J. Vet. Res. 1976;37: 1449–1453. [PubMed] [Google Scholar]
  24. Addie DD, Jarrett O. A study of naturally occurring feline coronavirus infections in kittens. Vet. Rec. 1992;130: 133–137. doi: 10.1136 / vr.130.7.133. [PubMed] [CrossRef] [Google Scholar]
  25. Worthing KA, et al. Risk factors for feline infectious peritonitis in Australian cats. J. Feline Med. Surg. 2012;14: 405–412. doi: 10.1177 / 1098612X12441875. [PubMed] [CrossRef] [Google Scholar]
  26. Rohrbach BW, et al. Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals. J. Am. Vet. Med. Assoc. 2001;218: 1111–1115. doi: 10.2460 / javma.2001.218.1111. [PubMed] [CrossRef] [Google Scholar]
  27. Grossman CJ. Interactions between the gonadal steroids and the immune system. Science. 1985;227: 257–261. doi: 10.1126 / science.3871252. [PubMed] [CrossRef] [Google Scholar]
  28. Bradshaw, JM, Pearson, GR & Gruffydd-Jones, TJ A Retrospective Study of 286 Cases of Neurological Disorders of the Cat. J. Comp. Pathol.131, 112–120. [PMC free article] [PubMed]
  29. Dean GA, Olivry T, Stanton C, Pedersen NC. In vivo cytokine response to experimental feline infectious peritonitis virus infection. Vet. Microbiol. 2003;97: 1–12. doi: 10.1016 / j.vetmic.2003.08.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  30. de Groot-Mijnes JDF, van Dun JM, van der Most RG, de Groot RJ. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J. Virol. 2005;79: 1036–1044. doi: 10.1128 / JVI.79.2.1036-1044.2005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  31. Vermeulen BL, et al. Suppression of NK cells and regulatory T lymphocytes in cats naturally infected with feline infectious peritonitis virus. Vet. Microbiol. 2013;164: 46–59. doi: 10.1016 / j.vetmic.2013.01.042. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  32. Hartmann K, et al. Comparison of different tests to diagnose feline infectious peritonitis. J. Vet. Intern. Med. 2003;17: 781–790. doi: 10.1111 / j.1939-1676.2003.tb02515.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  33. Hazuchova K, Held S, Neiger R. Usefulness of acute phase proteins in differentiating between feline infectious peritonitis and other diseases in cats with body cavity effusions. J. Feline Med. Surg. 2017;19: 809–816. doi: 10.1177 / 1098612X16658925. [PubMed] [CrossRef] [Google Scholar]
  34. Fischer Y, Sauter-Louis C, Hartmann K. Diagnostic accuracy of the Rivalta test for feline infectious peritonitis. Vet. Clin. Pathol. 2012;41: 558–567. doi: 10.1111 / j.1939-165X.2012.00464.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  35. Tasker S. Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests. J. Feline Med. Surg. 2018;20: 228–243. doi: 10.1177 / 1098612X18758592. [PubMed] [CrossRef] [Google Scholar]
  36. Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr. Opin. Virol. 2019;35: 57–62. doi: 10.1016 / j.coviro.2019.04.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Do pets protect their owners in the COVID-19 era?

Original article: Do pets protect their owners in the COVID-19 era?; 12.5.2020

Jan Jurgiel, Krzysztof J. Filipiak, Łukasz Szarpak, Miłosz Jaguszewski, Jacek Smereka, Tomasz Dzieciątkowskig

Introduction

The outbreak of COVID-19 and the global spread of SARS-CoV-2 occurred in Wuhan, China at the end of 2019. [1]. Following the infection of more than 120,000 people and nearly 5,000 dead, the World Health Organization has declared it a globally controllable pandemic [2]. In April 2020, the number of cases exceeded 2 million and the infection spread to more than 180 countries [3], [4]. Human coronaviruses (HCoV) have caused not only the current pandemic, but also the SARS and MERS epidemics, which have infected and claimed the lives of thousands of people. [5], [6]. Virological and genetic studies have confirmed that bats hosted both viruses, which spread further with civets and dromedaries. [7], [8], [9]. Recent studies suggest that specific animal species may be the source of different coronaviruses: bats for alpha- and beta-coronaviruses, birds for gamma- and delta-coronaviruses, and rodents for line A beta-coronavirus progenitors. [10], [11], [12].

The infection does not only affect wild animals and there are many known strains that affect livestock and domestic animals [13]. Symptoms caused by coronaviruses depend on the type of strain; may include gastrointestinal diseases (diarrhea, vomiting, anorexia), respiratory diseases (dyspnoea, cough, wheezing) and others. The animal origin of the new coronavirus has led to a discussion about the possible transmission of the disease through contact with domestic animals. General fear has increased after confirmation of SARS-CoV-2 in a tiger at a Bronx zoo [14]. In an effort to address these concerns, the World Health Organization has referred to a lack of evidence on the spread of the new coronavirus from pets to humans. [15].

Empirical observations indicate that the presence of domestic animals may have a positive effect on the course of COVID-19. Anecdotal evidence seeks to argue that COVID-19 only rarely affects veterinarians. In an interview, Sabina Olex-Condor, a Spanish doctor in Madrid, indicated that mildness was more common in pet-owned patients (available at: www.vetnolimits.com; www.psy.pl; www.plus.gloswielkopolski.pl) . The correlation between pet ownership and the moderate course of COVID-19 has not yet been confirmed. In our study, we went through a lot of literature and tried to find a possible explanation for this phenomenon. We hypothesize that contact with animal coronaviruses could lead to stimulation of the immune system, creating an effective response to SARS-CoV-2 infection.

Occurrence of animal coronavirus in domestic animals

A possible positive effect of animal ownership may be considered if the presence of animal coronaviruses in the pet population is high. Therefore, we studied works presenting the occurrence of animal coronaviruses. In our analysis, we focus on dogs for two reasons: 1) they are the most common species kept as pets [16], 2) canine coronaviruses can be easily transmitted to humans via drops. Feline coronaviruses are also detected in cats, but their symptoms are mainly related to the gastrointestinal tract or cause an unusual and usually fatal abnormal immune response to a viral infection, but animal-to-human transmission is very limited. [17].

Table 1 shows the detection rate in dogs. According to studies, detection of canine respiratory coronaviruses (CrCoV) is stable from 7.5% to 54.7%. Studies with the most significant sample (Priestnal et al. 2006 and More et al. 2020) showed detection: 54.7% for North America, 36.0% for the United Kingdom and 53.0% for New Zealand.

the authorNumber of samples (n)Detection rateMethodRegion
Priestnal et al. (2006) [18]1000
824
54.7%
36.0%
Serological testingNorth America
UK
More et al. (2020) [19]101553.0%Serological testingNew Zealand
Priestnal et al. (2007) [20]49023.3%Serological testingItaly
An et al. (2010) [21]48312.8%Serological testingKorea
Hielb et al. (2019) [22]2647.5%Serological testingAustria
Knesl et al. (2009) [23]25129.0%Serological testingNew Zealand
Mitchell et al. (2017) [24]24747.0%
7.7%
Serological testingEurope
Decarao et al. (2007) [25]21532.0%Serological testingItaly
Schulz et al. (2014) [26]1519.8%Molecular testingGermany
Erles et al. (2003) [27]11937.0%Molecular testingUK
Erles and Brownlie [28](2005)11338.9%Serological testingUK
Sowman et al. (2018) [29]9350.5%Serological testingNew Zealand
Wille et al. (2020) [30]8814.7%Molecular testingSweden
Table 1
Summary of coronavirus studies in dogs.

The data show that the incidence of CrCoV is high in dogs, which may indicate that people who have pets may have more frequent contact with different types of canine coronaviruses. Because infected pets may not have symptoms, owners' contact with pathogens may be asymptomatic.[31].

Cross-reactivity and mobilization of the immune system

The human immune system fights a variety of viral infections in three ways: 1) mediated by interferon, 2) mediated by cytotoxic cells, and 3) mediated by antibodies. [32]. The first is an interferon that provides an effective immune response by activating NK cells and macrophages, suppressing viral protein production, and regulating antigen presentation by T cells. Second, cytotoxic cells can directly kill virus-infected host cells with specific receptors and enzymes, stopping further infection. [33].

Antibody-mediated arrest of infection can be accomplished by various mechanisms: agglutination, phagocytosis, or complement systemic degradation, but all are stimulated by antibody opsonization. [32]. The effectiveness of this process is related to the specificity of the antibody - the ability of the antibody to distinguish between similar and different antigens. However, due to cross-reactivity, antibodies may react to another antigen due to the similarity of its structures [34]. A response to a similar antigen can lead to effective immune protection, as if it were performed against the primary target. Cross-reactivity is related to the degree of similarity of the primary antigen to the second, for example: neutralizing antibodies against the "old" SARS-CoV have a slight binding strength to the new coronavirus SARS-CoV-2.

The coronavirus genome encodes four structural and sixteen nonstructural proteins, approximately [35], [36]. Spike proteins (S-proteins) are structural proteins that recognize and attach to ACE2 located on the cell membrane of the airway epithelium and lung parenchyma. In their study, Tilocca and colleagues sequenced the amino acid sequence of SARS-CoV-2 and compared it with sequences derived from other animal coronaviruses. [37]. The analysis showed that the whole sequence similarity between SARS-CoV-2 and canine respiratory coronavirus (CrCoV) is 36,39% (comparison of GI protein QHR63290 with QAY30030). However, further investigation of the epitope sequence shows high homology: 57,14%, 80,00%, 83,33% and 100,00% in the CrCoV epitopes: 789-799, 754-764, 424-437 and 1139-1152. Based on the data, we hypothesize that repeated contact with animal coronaviruses may lead to immunization. This effect was confirmed by experimental studies. Research by Luo and colleagues showed that a CrCoV-derived nucleocapsid protein expressed in E. coli showed antigenic cross-reactivity with antisera against human coronaviruses [38].

Furthermore, Zhao and colleagues propose another explanation for the protective effect of contact with zoonotic coronaviruses [39]. Cross-reactivity with T-lymphocytes may elicit an immune response. CD4 + memory T cells in the airway epithelium can efficiently produce interferon-gamma, leading to the activation of other cells and an efficient response.

Thus, pet-owned patients may have had a mild course of SARS-CoV-2 infection, as observed in Spain. Repeated contact with pathogens can function as an immune mobilization against SARS-CoV-2 in many different ways.

Conclusions

  1. Canine respiratory coronaviruses are common in dogs.
  2. Ownership of the animal can lead to contact with canine coronaviruses.
  3. Repeated exposure to canine coronaviruses may stimulate the human immune system and provide an effective response to SARS-COV-2.
  4. A further examination of the correlation between pet ownership and the course of COVID-19 is needed. Such data, although recovered, is worth analyzing.

References

1. Wu Y.-C., Chen C.-S., Chan Y.-J. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020; 83: 217-220. [PMC free article] [PubMed] [Google Scholar]
2. WHO Coronavirus disease 2019 (COVID-19) Situation Report - 52.
3. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU).
4. Mallapaty S. What the cruise-ship outbreaks reveal about COVID-19. Nature. 2020; 580: 18. [PubMed] [Google Scholar]
5. Sorensen MD Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals. Ann NY Acad Sci. 2006; 1067: 500–505. [PMC free article] [PubMed] [Google Scholar]
6. http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html.
7. Yin Y., Wunderink RG MERS, SARS and other coronaviruses as causes of pneumonia: MERS, SARS and coronaviruses. Respirology. 2018; 23: 130–137. [PMC free article] [PubMed] [Google Scholar]
8. Li W. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310: 676–679. [PubMed] [Google Scholar]
9. Ithete NL Close relative of human middle east respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis. 2013; 19: 1697–1699. [PMC free article] [PubMed] [Google Scholar]
10. Woo PCY Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012; 86: 3995–4008. [PMC free article] [PubMed] [Google Scholar]
11. Woo PCY Molecular diversity of coronaviruses in bats. Virology. 2006; 351: 180–187. [PMC free article] [PubMed] [Google Scholar]
12. Lau SKP Discovery of a novel coronavirus, china rattus coronavirus HKU24, from Norway rats supports the murine origin of betacoronavirus 1 and has implications for the ancestor of betacoronavirus lineage A. J Virol. 2015; 89: 3076–3092. [PMC free article] [PubMed] [Google Scholar]
13. Wang Q., Vlasova AN, Kenney SP, Saif LJ Emerging and re-emerging coronaviruses in pigs. Curr Opin Virol. 2019; 34: 39–49. [PMC free article] [PubMed] [Google Scholar]
14. https://www.bbc.com/news/world-us-canada-52177586.
15. WHO Coronavirus disease (COVID-19) advice for the public: Myth busters.
16. Applebaum JW, Peek CW, Zsembik BA Examining US pet ownership using the General Social Survey. Soc Sci J. 2020; 1-10 doi: 10.1080 / 03623319.2020.1728507. [CrossRef] [Google Scholar]
17. Jaimes JA, Whittaker GR Feline coronavirus: insights into viral pathogenesis based on the spike protein structure and function. Virology. 2018; 517: 108–121. [PMC free article] [PubMed] [Google Scholar]
18. Priestnall S., Brownlie J., Dubovi E., Erles K. Serological prevalence of canine respiratory coronavirus. Vet Microbiol. 2006; 115: 43–53. [PMC free article] [PubMed] [Google Scholar]
19. More G., Dunowska M., Acke E., Cave N. A serological survey of canine respiratory coronavirus in New Zealand. New Zealand Vet J. 2020; 68: 54–59. [PMC free article] [PubMed] [Google Scholar]
20. Priestnall SL, Pratelli A., Brownlie J., Erles K. Serological prevalence of canine respiratory coronavirus in southern italy and epidemiological relationship with canine enteric coronavirus. J VET Diagn Invest. 2007; 19: 176–180. [PubMed] [Google Scholar]
21. An D.-J. A serological survey of canine respiratory coronavirus and canine influenza virus in Korean dogs. J Vet Med Sci. 2010; 72: 1217–1219. [PubMed] [Google Scholar]
22. Hiebl A. Detection of selected viral pathogens in dogs with canine infectious respiratory disease in Austria. J Small Anim Pract. 2019; 60: 594–600. [PMC free article] [PubMed] [Google Scholar]
23. Knesl O., Allan F., Shields S. The seroprevalence of canine respiratory coronavirus and canine influenza virus in dogs in New Zealand. New Zealand Vet J. 2009; 57: 295–298. [PubMed] [Google Scholar]
24. Mitchell JA European surveillance of emerging pathogens associated with canine infectious respiratory disease. Vet Microbiol. 2017; 212: 31–38. [PMC free article] [PubMed] [Google Scholar]
25. Decaro N. Serological and molecular evidence that canine respiratory coronavirus is circulating in Italy. Vet Microbiol. 2007; 121: 225–230. [PMC free article] [PubMed] [Google Scholar]
26. Schulz BS, Kurz S., Weber K., Balzer H.-J., Hartmann K. Detection of respiratory viruses and Bordetella bronchiseptica in dogs with acute respiratory tract infections. Vet J. 2014; 201: 365–369. [PMC free article] [PubMed] [Google Scholar]
27. Erles K., Toomey C., Brooks HW, Brownlie J. Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease. Virology. 2003; 310: 216–223. [PMC free article] [PubMed] [Google Scholar]
28. Erles K., Brownlie J. Investigation into the causes of canine infectious respiratory disease: antibody responses to canine respiratory coronavirus and canine herpesvirus in two kennelled dog populations. Arch Virol. 2005; 150: 1493–1504. [PMC free article] [PubMed] [Google Scholar]
29. Sowman H., Cave N., Dunowska M. A survey of canine respiratory pathogens in New Zealand dogs. New Zealand Vet J. 2018; 66: 236–242. [PubMed] [Google Scholar]
30. Wille M. Evolutionary genetics of canine respiratory coronavirus and recent introduction into Swedish dogs. Infect Genet Evol. 2020; 82 [PMC free article] [PubMed] [Google Scholar]
31. Buonavoglia C. Canine coronavirus highly pathogenic for dogs. Emerg Infect Dis. 2006; 12: 492–494. [PMC free article] [PubMed] [Google Scholar]
32. https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-disease/immune-responses-bacteria.
33. Rosendahl Huber S., van Beek J., de Jonge J., Luytjes W., van Baarle D. T cell responses to viral infections - opportunities for peptide vaccination. Front. Immunol. 2014; 5 [PMC free article] [PubMed] [Google Scholar]
34. Frank SA Princeton University Press; 2002. Immunology and evolution of infectious disease. [Google Scholar]
35. Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020; 92: 418–423. [PMC free article] [PubMed] [Google Scholar]
36. Donnelly CA Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis. 2004; 4: 672–683. [PMC free article] [PubMed] [Google Scholar]
37. Tilocca B. Molecular basis of COVID-19 relationships in different species: a one health perspective. Microbes Infect. 2020 doi: 10.1016 / j.micinf.2020.03.002. S1286457920300484. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Lu S. Genetic and antigenic characterization of recombinant nucleocapsid proteins derived from canine coronavirus and canine respiratory coronavirus in China. Sci China Life Sci. 2016; 59: 615–621. [PMC free article] [PubMed] [Google Scholar]
39. Zhao J. Airway memory CD4 + T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016; 44: 1379–1391. [PMC free article] [PubMed] [Google Scholar]

FIP In Aged Cats

Original article: 2021 - FIP IN AGED CATS
Niels C. Pedersen, DVM, PhD, Professor Emeritus, University of California School of Veterinary Medicine, Davis; 2/11/2021

Facts: The relationship between age and the incidence of FIP has already been discussed in the literature and has even been the subject of research [1]. 29% cases of FIP occur in kittens up to 0.5 years, 50% up to 1 year, 80% up to 3 years of age and 96% up to 8 years of age (Table 1). The incidence of FIP between the ages of 7 and 11 is extremely low. At least two studies, one from the United States in 1976 [2] and the other from Europe in 2021 [3] [Table 1], confirm a real but less dramatic increase in the incidence of 3% in older cats. The purpose of this article is to discuss the causes of this increase and its implications for the diagnosis and successful treatment of FIP in old cats.

Table 1. Age of cats at the time of FIP diagnosis based on data obtained from cats treated with GS-441524 from Europe 2019-2021.

Source of FIP exposure: FIP is the result of FECV exposure [4] and the same applies to older cats. However, there are several unique situations associated with such exposure. The first scenario is analogous to that which occurs in younger cats, ie mass exposure of younger cats. However, it is common for older cats to mate as kittens and live their lives together in relative isolation. This leads to another interesting scenario in which one cat in a pair is likely to die sooner than the other, leaving her without a companion. You will then get a new companion, most often a kitten, from a rescue organization, shelter or kennel. The chances of the kitten excluding FECV from these sources are high. There is also a second source of FECV exposure that does not require cat-to-cat contact. It is known that FECV can be transmitted from one cat to another through human clothing. FECV is present in high concentrations in litter dust, especially in young cats and kittens, and can survive for many days in the environment. Therefore, the owner's contact with younger cats away from home is another source of FECV infection.

Unique aspects of FIP in old cats: Experience with the treatment of old cats GS-441524 leads to three possible factors that should interest us: 1) misdiagnosed FIP, 2) the existence of FIP in connection with one or more other disorders common in the aging cat and 3) treatment of FIP in connection with weakened immune system.

Incorrect FIP diagnosis: Observations made in cats treated with GS-441524 suggest that FIP in older cats is more prone to misdiagnosis and more difficult to treat. The misdiagnosis of FIP in old cats can best be explained by a simple probability. For example, one study found that FIP is the most common cause of spinal disease in cats less than two years old, while cancer was the most common single disorder in the 2-8 age group [5]. Therefore, the first consideration for a spinal cord disorder in a young cat should be FIP, while the first consideration for an old cat should be cancer. The incidence of many non-retroviral cancers is also on the rise, starting at around 7-9 years of age, accounting for about one-third of deaths in old cats. Chronic kidney disease also begins to manifest clinically at about the same age and accounts for about one-third of deaths in old cats. Remaining deaths in old cats include diabetes and hyperthyroidism and numerous musculoskeletal, cardiovascular, neurological and gastrointestinal disorders. Older cats, like older people, tend to have a decrease in immune function, which is often manifested by increased serum immunoglobulin levels and diseases associated with relative immunodeficiency and autoimmunity. The clinical and laboratory symptoms of these aging disorders often mimic the symptoms of FIP, but the probability that aging cats will have FIP is much lower than in these other conditions. In contrast, a young cat with FIP-compatible clinical and laboratory features that has FIP is much higher than an old cat with similar findings.

FIP as a secondary disease: The second scenario is more common in many old cats with FIP suffering from other serious medical conditions. Chronic renal failure is the most common of these underlying conditions, with cancers such as lymphoma being uncommon. Older cats also suffer from an aging immune system, leading to a state of relative immunodeficiency, which is another predisposing factor for FIP.

FIP and immunodeficiency due to aging: The immune system is sensitive to the adverse effects of aging in all animal species, including cats [6, 7]. Decreased immune function in aging cats is associated with changes in B and T cell populations and increased levels of non-specific immunoglobulin. Therefore, older cats often have higher levels of serum protein and globulin than usual. Increases in total serum protein and globulin levels in younger cats are often considered symptoms of FIP, while their diagnostic value in older cats is less significant.

The relative immunodeficiency caused by aging makes it difficult to fight new infections and older infections that remain hidden or latent in the body for decades. The best studied examples of the impact of aging on resistance to new and latent infections come from humans. COVID-19 deaths in the elderly with complicating diseases such as diabetes and chronic lung disease are the best examples of the impact of aging and chronic degenerative diseases on resistance to infectious agents. It is well known that tuberculosis remains latent in the pulmonary lymph nodes for decades before reactivation. Therefore, TB is a particular problem in humans in facilities for the elderly and in individuals treated for autoimmune disorders with cytokine inhibitors. There are also indications that FIP in some cats may exist in a subclinical state for months to years before it becomes clinically evident. There are also cases of cats that live their entire lives in residential isolation until they develop FIP in old age.

Conclusion: Fortunately, FIP in old cats is unusual, but it has unique properties that affect diagnosis and treatment. Particular attention should be paid to verifying the diagnosis of FIP and identifying other health factors that either predispose to FIP or complicate its successful treatment. This is a major diagnostic challenge in older cats and other degenerative disorders common to this age group make treatment difficult. The FIP cure rate, which is higher than 80% in young cats, is not as high in old cats.

References

  1. Pedersen NC, Liu H, Gandolfi B, Lyons LA. The influence of age and genetics on natural
    resistance to experimentally induced feline infectious peritonitis. Vet Immunol Immunopathol.
    2014, 162(1-2):33-40.
  2. Pedersen NC. Feline infectious peritonitis. Something old, something new. Feline
    Practice. 1976, 6: 42-51.
  3. FIP Warriors CZ / SK. 2021. Statistics on FIP treatment in the Czech & Slovak Republics.
    https://www.fipwarriors.eu/en/stats/.
  4. Pedersen NC. Virologic and immunologic aspects of feline infectious peritonitis virus infection.
    Adv Exp Med Biol. 1987, 218: 529-50.
  5. Marioni-Henry K, Vite CH, Newton AL, Van Winkle TJ. Prevalence of diseases of
    the spinal cord of cats. Journal Veterinary Internal Medicine, 2004, 18, 851-58.
  6. Day MJ. Aging, immunosenescence and inflammageing in the dog and cat. J Comp
    Pathol. 2010, 142 Suppl 1: S60-9.
  7. Cornell Feline Health Center. The Special Needs of the Senior Cat. 2016.
    https://www.vet.cornell.edu/departments-centers-and-institutes/cornell-feline-healthcenter/health-information/feline-health-topics/special-needs-senior-cat

FIP infection and immunity

Original article: FIP infection and immunity (2010)

Immunity to FIP virus (FIPV) infection is a fascinating topic for several reasons. First, humoral immunity does not appear to be important in protection but may actually contribute to the course of the disease. Second, protective immunity appears to be largely cell-mediated and may be of an infectious-type, “premonition” type. Third, the type and strength of immunity appears to determine the form that FIPV infection will take.[1]. There is a reasonable assumption that strong humoral (nonspecific) immunity with very weak or no cellular immunity will lead to effusion FIP, humoral immunity with moderate cellular immunity will lead to non-effusive FIP, and humoral immunity with strong cellular immunity will prevent the disease. Although these are mainly working hypotheses, there is fairly convincing evidence for each[2].

Antibodies against FIPV antigens participate in two different immune processes, neither of which correlates with immunity. The first process is an Arthus-type hypersensitivity reaction targeting small venules, while the second process is an antibody-mediated increase in viral uptake and replication by macrophages. All three components of the Arthus-type response, antigen, complement, and antibody, are present at high levels in the lesions, particularly in cats with effusion FIP. Arthus reactions are characterized by vasculitis, swelling, migration of inflammatory cells and necrosis. Antibody-mediated exacerbation of the disease was already described by Pedersen and Boyle. They found that the occurrence of antibodies and symptoms of the disease were always closely related. Seronegative (naïve) cats developed the earliest signs of FIP within 10-16 days or more after experimental infection, and the timing of disease always coincided with the appearance of antibodies. Healthy cats positive for FCoV antibodies (ie, exposed to FECV) were then challenged with FIPV. The phenomenon of antibody-mediated disease progression was later confirmed to involve antibodies against specific epitopes on the spike protein; these antibodies also functioned as neutralizing antibodies in vitro. Macrophage infection in vitro was significantly enhanced by the addition of immune serum. This led to a plausible theory in which virus particles coated with antibody and complement were absorbed through fc receptors on macrophages by a process of endocytosis[3]. Thus, FIPV enters the host cell at which point the virus spreads to other sites in the body through macrophage migration. Antibody-mediated enhancement of macrophage infarction appears to be serotype-specific, ie an antibody to FIPV serotype II only increases macrophage infection of FIPV serotype II[4].

Antibody-mediated immunopathogenesis in effusion FIP and the role of macrophages in the disease appear to be similar to those described in Dengue hemorrhagic shock syndrome (Halstead, 1979). Arthus-type reaction is a hallmark of Dengue shock disease syndrome and effusion FIP. Virus-loaded macrophages, viral particles, and viral proteins accumulate around small veins. These localized sources of antigens, as well as antigens in the blood, can complement each other and form immunocomplexes. As a result, immune complexes accumulate around small venules and trigger the release of specific macrophage factors that cause tissue damage. Paltrinieri et al. (1998) also demonstrated that FIP lesions contained many virus-infected macrophages, and that extracellular viral antigens were detectable in foci along with necrosis. Necrosis is one of the hallmarks of Arthus-type vasculitis[5].

Although much work has been done in the field of antibody-mediated FIP potentiation, naturally occurring FIP may be of a different nature than in the laboratory. This phenomenon has been described mainly between certain FCoV isolates and unknown FECV strains. In general, the more virulent the FIPV isolate, it is shown that the more likely it is to respond to antibody amplification (Pedersen, 2009). If humoral immunity does not protect cats from virulent FIPV strains, then what is the nature of immunity to FIPV? Immunity to FIPV is thought to be largely cell mediated. Reasons for this assumption include:

  • The non-fusion form of FIP resembles tuberculosis and deep fungal infections in humans and animals, and immunity to these infections is known to involve primarily cellular mechanisms.
  • Dry FIP lesions resemble type IV hypersensitivity reactions with central macrophages containing relatively small amounts of virus and surrounded by dense infiltrates of plasma cells and CD4 + lymphocytes, whereas wet FIP pyogranulomas are aggregates of virus-filled and mainly neutrophil-mediated macrophages.
  • The clinical incidence of FIP may be significantly increased by co-infection with FeLV. FeLV infection is a potent suppressor of cellular immunity and T-cell mediated humoral immunity.
  • FIP immunity cannot be transmitted passively to hyperimmune sera, regardless of whether the serum is collected from FECV-infected cats or cats that have survived FIPV exposure.
  • The delayed-type hypersensitivity reaction to FIP antigens can be induced in association with cats immune to FIP, and the peripheral blood lymphocytes of the obtained cats respond to the FIPV antigen in vitro.
  • Cats are known to be carriers of FIPV in the form of a latent or latent infection, and this infection can be reactivated by infecting such carriers with FeLV but not methylprednisolone acetate.[6].

A second type of carrier state is known to exist in infections such as tuberculosis, blastomycosis, histoplasmosis and coccidioidomycosis, and immunity in these situations is maintained by the persistence of small numbers of organisms in the mesenteric or bronchial lymph nodes. This type of immunity, called “premonition” (intuitive) or infectious immunity, persists only as long as the intracellular pathogens persist in a reactivable form (Pedersen, 1987). The same phenomenon has probably been observed in cats immunized with live FIPV with modified virulence. Immunized cats showed no outward signs of disease when challenged with virulent FIPV even after four months, but residual FIP lesions were confirmed histologically.[7].

DeGroot-Mijnes et al. (2005) presented a unified concept of T-cell responses in FIP. They postulated that virus-induced T cell depletion and T cell antiviral response are conflicting forces and that the effectiveness of early T cell responses critically determines the outcome of the infection. If the virus wins, FIP will occur, while if the host wins, no disease will develop. They observed a consistent increase in viral RNA levels in the blood of end-stage FIP cats, suggesting that the fatal disease is directly related to loss of immune control and uncontrolled circular replication. Paltrinieri et al. (1998) analyzed lymphocyte subsets of CD5, CD4, CD8, CD21 markers by flow cytometry [8]. Cats recently infected with FECV that did not develop FIP showed a moderate increase in T cells. FECV-infected cats with a high prevalence of FIP showed a slight and persistent decrease in T cell subsets, while cats with FIP had a significant decrease in all lymphocyte subsets. Of course, using the approach of whether a chicken or an egg was used before, it can be argued that the level of viremia determines the outcome. [9].

Both genetic and host factors appear to have a strong influence on resistance or susceptibility to naturally occurring FIPV. FIP studies at many purebred Persian kennels have shown that susceptibility is hereditary and accounts for about 50% in the incidence of the disease. [10]. Addie et al. (2004) attempted to associate disease susceptibility with certain alleles in the feline MHC DRB gene (feline leukocyte antigen or FLA). Individual cats have been shown to have between two and six FLA-DRB alleles, but no specific allele appears to be related to either FIP development, FCoV resistance in general, or FECV carrier status. However, this was only a pilot study with a limited number of cats or a small study size to conclude that genetic differences in the FLA complex are not part of the FIP. Cats that developed FIP after natural FCoV exposure were reported to have a significantly higher rate of viral replication or reduced viral clearance capacity than cats that were exposed to the virus but did not develop FIP; indicating a host factor [11].

References

  1.  Kipar, A et al (2006) FCoV infection: cats with FIP exhibit significantly higher viral loads than healthy infected cats. JFMS 8:69-72
  2. ↑ Benetka, V et al (2006) M gene analysis of atypical strains of feline and canine coronavirus circulating in an Austrian animal shelter. Vet Rec 159:170-174
  3. ↑ Olsen CW et al (1992) Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 66:956-965
  4. ↑ Motokawa K et al (1996) Comparison of the amino acid sequence and phylogenetic analysis of the peplomer, integral membrane and nucleocaspid proteins of feline, canine and porcine cornaviruses. Microbiol Immunol 40:425-433
  5. ↑ Lin, CN et al (2009) Field strain feline coronaviruses with small deletions in ORF7b
  6. ↑ Dr Addie.com
  7. ↑ Pedersen NC (1976) Feline infectious peritonitis. Something old, something new. Feline Practice6:42-51
  8. ↑ de Groot RJ & Horzinek MC (1995) Feline Infectious Peritonitis. In: Siddell, SG ed. The Coronaviridae: a review of coronaviruses and toroviruses. New York, Plenum Press pp: 294
  9. ↑ Pedersen NC et al (1981) Infection studies in kittens utilizing feline infectious peritonitis virus propogated in cell culture. Am J Vet Res 42:363-367
  10. ↑ Martin ML (1985) Coronavirus enteritis and a recent outbreak following modified live virus vaccination. Compend Cont Educ Pract VetItalic text 7:1012-1017
  11. ↑ Paltrinieri, S et al (1998) Some aspects of humoral and cellular immunity in naturally occurring feline infectious peritonitis. Vet Immunol Immunopathol 65:205-220
en_GBEN